| Year |
Citation |
Score |
| 2023 |
Baker SD, Bates SE, Brooks GA, Dahut WL, Diasio RB, El-Deiry WS, Evans WE, Figg WD, Hertz DL, Hicks JK, Kamath S, Kasi PM, Knepper TC, McLeod HL, O'Donnell PH, et al. Testing: Time to Put Patient Safety First. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2202364. PMID 36821823 DOI: 10.1200/JCO.22.02364 |
0.437 |
|
| 2022 |
Schmidt KT, Karzai F, Bilusic M, Cordes LM, Chau CH, Peer CJ, Wroblewski S, Huitema ADR, Schellens JHM, Gulley JL, Dahut WL, Figg WD, Madan RA. A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide. The Oncologist. PMID 35640474 DOI: 10.1093/oncolo/oyac100 |
0.305 |
|
| 2020 |
Wei BR, Hoover SB, Peer CJ, Dwyer JE, Adissu HA, Shankarappa P, Yang H, Lee M, Peat TJ, Figg WD, Simpson RM. Efficacy, tolerability and pharmacokinetics of combined targeted MEK and dual mTORC1/2 inhibition in a preclinical model of mucosal melanoma. Molecular Cancer Therapeutics. PMID 32943547 DOI: 10.1158/1535-7163.Mct-19-0858 |
0.317 |
|
| 2020 |
Hassan R, Alewine C, Mian I, Spreafico A, Siu LL, Gomez-Roca C, Delord JP, Italiano A, Lassen U, Soria JC, Bahleda R, Thomas A, Steinberg SM, Peer CJ, Figg WD, et al. Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin. Cancer. PMID 32870522 DOI: 10.1002/Cncr.33145 |
0.315 |
|
| 2020 |
Chau V, Madan RA, Figg WD. Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer. Cancer Biology & Therapy. 1-4. PMID 32844710 DOI: 10.1080/15384047.2020.1809913 |
0.407 |
|
| 2020 |
Handy WF, Schmidt KT, Price DK, Figg WD. Examining HSD3B1 as a possible biomarker to detect prostate cancer patients who are likely to progress on ADT. Cancer Biology & Therapy. 1-3. PMID 32791030 DOI: 10.1080/15384047.2020.1796195 |
0.428 |
|
| 2020 |
Risdon EN, Chau CH, Price DK, Sartor O, Figg WD. PARP Inhibitors & Prostate Cancer: To Infinity and Beyond BRCA. The Oncologist. PMID 32790034 DOI: 10.1634/Theoncologist.2020-0697 |
0.347 |
|
| 2020 |
Apolo AB, Nadal R, Tomita Y, Davarpanah NN, Cordes LM, Steinberg SM, Cao L, Parnes HL, Costello R, Merino MJ, Folio LR, Lindenberg L, Raffeld M, Lin J, Lee MJ, ... ... Figg WD, et al. Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. The Lancet. Oncology. PMID 32645282 DOI: 10.1016/S1470-2045(20)30202-3 |
0.317 |
|
| 2020 |
Cheong EJY, Nair PC, Neo RWY, Tu HT, Lin F, Chiong E, Esuvaranathan K, Fan H, Szmulewitz R, Peer CJ, Figg WD, Chai CLL, Miners JO, Chan ECY. Slow tight binding inhibition of CYP17A1 by abiraterone redefines its kinetic selectivity and dosing regimen. The Journal of Pharmacology and Experimental Therapeutics. PMID 32554434 DOI: 10.1124/Jpet.120.265868 |
0.328 |
|
| 2020 |
Madan RA, Schmidt KT, Karzai F, Peer CJ, Cordes LM, Chau CH, Steinberg SM, Owens H, Eisner J, Moore WR, Dahut WL, Gulley JL, Figg WD. Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment. Clinical Genitourinary Cancer. PMID 32327394 DOI: 10.1016/J.Clgc.2019.11.002 |
0.434 |
|
| 2020 |
Hawley JE, Pan S, Figg WD, Lopez-Bujanda ZA, Strope JD, Aggen DH, Dallos MC, Lim EA, Stein MN, Hu J, Drake CG. Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy. The Prostate. PMID 31899823 DOI: 10.1002/Pros.23948 |
0.403 |
|
| 2020 |
Rodgers LT, Lester McCully CM, Odabas A, Cruz R, Peer CJ, Figg WD, Warren KE. Characterizing the pharmacokinetics of panobinostat in a non-human primate model for the treatment of diffuse intrinsic pontine glioma. Cancer Chemotherapy and Pharmacology. PMID 31894347 DOI: 10.1007/S00280-019-04021-Y |
0.324 |
|
| 2020 |
Gandhy SU, Karzai F, Marte JL, Bilusic M, McMahon S, Strauss J, Couvillon A, Williams M, Hankin A, Steinberg SM, Figg WD, Arlen PM, Dahut WL, Gulley JL, Madan RA. PSA progression compared to radiographic or clinical progression in metastatic castration-resistant prostate cancer patients treated with enzalutamide. Journal of Clinical Oncology. 38: 105-105. DOI: 10.1200/Jco.2020.38.6_Suppl.105 |
0.413 |
|
| 2020 |
Gandhy SU, Karzai F, Marte JL, Bilusic M, McMahon S, Strauss J, Couvillon A, Williams M, Hankin A, Steinberg SM, Gill A, Tubbs A, Schonhoft J, Figg WD, Arlen PM, et al. Evaluating biomarkers in metastatic castration-resistant prostate cancer patients treated with enzalutamide: PSA, circulating tumor cell counts, AR-V7 status and radiographic progression. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.E17569 |
0.411 |
|
| 2020 |
Pegna GJ, Ahmad MI, Yu Y, Yuno A, Lee M, Peer CJ, Steinberg SM, Cao L, Trepel JB, Figg WD, Hassan R, Pastan I, Alewine CC. Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion with or without nab-paclitaxel. Journal of Clinical Oncology. 38: 3553-3553. DOI: 10.1200/Jco.2020.38.15_Suppl.3553 |
0.379 |
|
| 2020 |
Ramaswami R, Lurain KA, Widell A, Goncalves PH, Ekwede I, Figg WD, Peer CJ, Mangusan R, George J, Steinberg SM, Khetani V, Whitby D, Uldrick TS, Yarchoan R. A phase I trial of pomalidomide in combination with liposomal doxorubicin in patients with Kaposi sarcoma with or without other KSHV-associated diseases. Journal of Clinical Oncology. 38: 11552-11552. DOI: 10.1200/Jco.2020.38.15_Suppl.11552 |
0.36 |
|
| 2020 |
Wedekind MF, Del Rivero J, Arnaldez FI, Srinivasan R, Spencer M, Steinberg SM, Peer CJ, Figg WD, Killian JK, Meltzer PS, Linehan WM, Widemann BC, Glod J. A phase II trial of the DNA methyl transferase inhibitor, SGI-110 (Guadecitabine), in children and adults with SDH-deficient GIST, pheochromocytoma, and paraganglioma, and HLRCC-associated kidney cancer. Journal of Clinical Oncology. 38: 11540-11540. DOI: 10.1200/Jco.2020.38.15_Suppl.11540 |
0.367 |
|
| 2019 |
Schmidt KT, Peer CJ, Huitema ADR, Williams MD, Wroblewski S, Schellens JHM, Madan RA, Figg WD. Measurement of NLG207 (formerly CRLX101) nanoparticle-bound and released camptothecin in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 181: 113073. PMID 31927166 DOI: 10.1016/J.Jpba.2019.113073 |
0.373 |
|
| 2019 |
Alewine C, Ahmad M, Peer CJ, Hu ZI, Lee MJ, Yuno A, Kindrick JD, Thomas A, Steinberg SM, Trepel JB, Figg WD, Hassan R, Pastan I. Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with nab-paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31792036 DOI: 10.1158/1078-0432.Ccr-19-2586 |
0.331 |
|
| 2019 |
Huang PA, Beedie SL, Chau CH, Venzon DJ, Gere S, Kazandjian D, Korde N, Mailankody S, Landgren O, Figg WD. Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide. Scientific Reports. 9: 14884. PMID 31619706 DOI: 10.1038/S41598-019-51446-9 |
0.323 |
|
| 2019 |
Knechel MA, Schmidt KT, Figg WD. Combination treatment in metastatic castration-resistant prostate cancer: can we safely boost efficacy by adding radium-223? Cancer Biology & Therapy. 1-3. PMID 31530074 DOI: 10.1080/15384047.2019.1665395 |
0.351 |
|
| 2019 |
Chau CH, Steeg PS, Figg WD. Antibody-drug conjugates for cancer. Lancet (London, England). 394: 793-804. PMID 31478503 DOI: 10.1016/S0140-6736(19)31774-X |
0.318 |
|
| 2019 |
Peer CJ, Schmidt KT, Kindrick JD, Eisner JR, Brown VV, Baskin-Bey E, Madan R, Figg WD. A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer. Cancer Chemotherapy and Pharmacology. PMID 31367790 DOI: 10.1007/S00280-019-03908-0 |
0.414 |
|
| 2019 |
Komiya T, Memmott RM, Blumenthal GM, Bernstein W, Ballas MS, De Chowdhury R, Chun G, Peer CJ, Figg WD, Liewehr DJ, Steinberg SM, Giaccone G, Szabo E, Kawabata S, Tsurutani J, et al. A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer. Translational Lung Cancer Research. 8: 247-257. PMID 31367538 DOI: 10.21037/Tlcr.2019.04.19 |
0.316 |
|
| 2019 |
Floudas CS, Brar G, Mabry-Hrones D, Duffy AG, Wood B, Levy E, Krishnasamy V, Fioravanti S, Bonilla CM, Walker M, Morelli MP, Kleiner DE, Steinberg SM, Figg WD, Greten TF, et al. A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer. PMID 31351862 DOI: 10.1016/J.Clcc.2019.06.004 |
0.346 |
|
| 2019 |
Li M, Nguyen L, Subramaniyan B, Bio M, Peer CJ, Kendrick J, Figg WD, Woo S, You Y. PBPK modeling-based optimization of site-specific chemo-photodynamic therapy with far-red light-activatable paclitaxel prodrug. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 31299262 DOI: 10.1016/J.Jconrel.2019.07.010 |
0.34 |
|
| 2019 |
Sissung TM, Huang PA, Hauke RJ, McCrea EM, Peer CJ, Barbier RH, Strope JD, Ley AM, Zhang M, Hong JA, Venzon D, Jackson JP, Brouwer KR, Grohar P, Glod J, ... ... Figg WD, et al. Severe Hepatotoxicity of Mithramycin Therapy Caused by Altering Expression of Hepatocellular Bile Transporters. Molecular Pharmacology. PMID 31175181 DOI: 10.1124/Mol.118.114827 |
0.329 |
|
| 2019 |
Conlon KC, Potter EL, Pittaluga S, Lee CR, Miljkovic MD, Fleisher TA, Dubois S, Bryant BR, Petrus M, Perera LP, Hsu J, Figg WD, Peer CJ, Shih JH, Yovandich JL, et al. IL-15 by continuous i.v. infusion to adult patients with solid tumors in a Phase I trial induced dramatic NK cell subset expansion. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31142503 DOI: 10.1158/1078-0432.Ccr-18-3468 |
0.347 |
|
| 2019 |
Lampert EJ, Hays JL, Kohn EC, Annunziata CM, Minasian L, Yu M, Gordon N, Sissung TM, Chiou VL, Figg WD, Houston N, Lee JM. Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk. Oncotarget. 10: 2855-2868. PMID 31080557 DOI: 10.18632/Oncotarget.26869 |
0.374 |
|
| 2019 |
Masiero L, Figg WD, Kohn EC. New anti-angiogenesis agents: review of the clinical experience with carboxyamido-triazole (CAI), thalidomide, TNP-470 and interleukin-12. Angiogenesis. 1: 23-35. PMID 14517390 DOI: 10.1023/A:1018301031580 |
0.382 |
|
| 2019 |
Chen G, VanderWeele DJ, Karzai F, Bilusic M, Al Harthy M, Arlen PM, Rosner IL, Chun G, Owens H, Couvillon A, Hankin A, Williams M, Cordes LM, Figg WD, Gulley JL, et al. Efficacy of abiraterone and enzalutamide in patients who had disease progression within twelve months of completing docetaxel for metastatic castration sensitive prostate cancer. Journal of Clinical Oncology. 37: 241-241. DOI: 10.1200/Jco.2019.37.7_Suppl.241 |
0.402 |
|
| 2019 |
Harthy MA, Madan RA, Karzai F, Petrylak DP, Kim JW, Arlen PM, Theoret MR, Marte J, Bilusic M, Couvillon A, Chun G, Owens H, Hankin A, Cordes LM, Figg WD, et al. A phase I and randomized phase II study of cabozantinib plus docetaxel and prednisone (C+DP) versus docetaxel and prednisone (DP) alone in metastatic castrate-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 37: 173-173. DOI: 10.1200/Jco.2019.37.7_Suppl.173 |
0.373 |
|
| 2019 |
Alewine CC, Hassan R, Ahmad MI, Trepel JB, Peer C, Figg WD, Pastan I. A phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with nab-paclitaxel for patients with previously treated advanced pancreatic cancer. Journal of Clinical Oncology. 37: 307-307. DOI: 10.1200/Jco.2019.37.4_Suppl.307 |
0.39 |
|
| 2019 |
Hawley J, Pan S, Figg WD, Lopez Bujanda Z, Strope J, Fojo AT, Dallos M, Aggen DH, Lim EA, Stein MN, Hu J, Drake CG. Correlation between innate cytokine levels and progression in men with biochemically recurrent prostate cancer treated with intermittent hormonal therapy. Journal of Clinical Oncology. 37: e16554-e16554. DOI: 10.1200/Jco.2019.37.15_Suppl.E16554 |
0.363 |
|
| 2019 |
Lurain K, Ramaswami R, Widell A, Ekwede I, George J, Stetler-Stevenson M, Raffeld M, Yuan CM, Ziegelbauer J, Maldarelli F, Figg WD, Peer C, Steinberg SM, Whitby D, Uldrick TS, et al. Phase I/II Study of Lenalidomide Combined with DA-EPOCH and Rituximab (DA-EPOCH-R2) in Primary Effusion Lymphoma in Patients with or without HIV Blood. 134: 4096-4096. DOI: 10.1182/Blood-2019-122070 |
0.35 |
|
| 2019 |
Alewine CC, Ahmad M, Peer CJ, Hu Z, Lee M, Yuno A, Kindrick J, Thomas A, Steinberg S, Trepel JB, Figg WD, Hassan R, Pastan I. Abstract PR07: Phase I/II study of mesothelin-targeted immunotoxin LMB-100 with nab-paclitaxel for patients with advanced pancreatic adenocarcinoma Cancer Research. 79. DOI: 10.1158/1538-7445.Panca19-Pr07 |
0.396 |
|
| 2019 |
Alewine C, Ahmad MI, Peer CJ, Steinberg S, Figg WD, Hassan R, Pastan I. Abstract A081: Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-A081 |
0.384 |
|
| 2019 |
Barbier RH, McCrea EM, Strope JD, Huang PA, Sissung TM, Price DK, Chau CH, Figg WD. Abstract A069: Mechanisms governing the transcriptional regulation of the liver-specific transporter OATP1B3 in prostate cancer Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-A069 |
0.396 |
|
| 2018 |
Al Harthy M, Singh H, Karzai F, Arlen P, Theoret M, Marte J, Bilusic M, Couvillon A, Owens H, Hankin A, Cordes L, Rosner I, Strauss J, Figg WD, Schlom J, et al. Intermittent short course enzalutamide in biochemically recurrent prostate cancer: Analysis of PSA recovery, testosterone levels and tolerability. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii297. PMID 32136685 DOI: 10.1093/Annonc/Mdy284.059 |
0.381 |
|
| 2018 |
Xie C, Duffy AG, Mabry-Hrones D, Wood B, Levy E, Krishnasamy V, Khan J, Wei JS, Agdashian D, Tyagi M, Gangalapudi V, Fioravanti S, Walker M, Anderson V, Venzon D, ... Figg WD, et al. Tremelimumab in combination with microwave ablation in patients with refractory biliary tract cancer. Hepatology (Baltimore, Md.). PMID 30578687 DOI: 10.1002/Hep.30482 |
0.388 |
|
| 2018 |
Petrovics G, Price DK, Lou H, Chen Y, Garland L, Bass S, Jones K, Kohaar I, Ali A, Ravindranath L, Young D, Cullen J, Dorsey TH, Sesterhenn IA, Brassell SA, ... ... Figg WD, et al. Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population. Prostate Cancer and Prostatic Diseases. PMID 30542053 DOI: 10.1038/S41391-018-0114-1 |
0.328 |
|
| 2018 |
Kazandjian D, Korde N, Mailankody S, Hill E, Figg WD, Roschewski M, Landgren O. Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial. Jama Oncology. PMID 30477009 DOI: 10.1001/Jamaoncol.2018.5457 |
0.317 |
|
| 2018 |
McCrea EM, Lee DK, Sissung TM, Figg WD. Precision medicine applications in prostate cancer. Therapeutic Advances in Medical Oncology. 10: 1758835918776920. PMID 29977347 DOI: 10.1177/1758835918776920 |
0.398 |
|
| 2018 |
Peer CJ, Hall OM, Sissung TM, Piekarz R, Balasubramaniam S, Bates SE, Figg WD. A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat. Cancer Chemotherapy and Pharmacology. PMID 29951694 DOI: 10.1007/S00280-018-3631-7 |
0.314 |
|
| 2018 |
Alyamani M, Emamekhoo H, Park S, Taylor J, Almassi N, Upadhyay S, Tyler A, Berk MP, Hu B, Hwang TH, Figg WD, Peer CJ, Chien C, Koshkin VS, Mendiratta P, et al. HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer. The Journal of Clinical Investigation. PMID 29939161 DOI: 10.1172/Jci98319 |
0.358 |
|
| 2018 |
Huang PA, Price DK, Figg WD. Molecular drivers of metastatic castrate-resistant prostate cancer: New roads to resistance. Cancer Biology & Therapy. 1-2. PMID 29757697 DOI: 10.1080/15384047.2018.1449618 |
0.355 |
|
| 2018 |
Chau CH, Figg WD. Revisiting 5α-reductase inhibitors and the risk of prostate cancer. Nature Reviews. Urology. PMID 29740116 DOI: 10.1038/S41585-018-0018-9 |
0.392 |
|
| 2018 |
Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, Harvey RD, Fishkin P, Yong WP, Chiong E, Nabhan C, Karrison T, Figg WD, Stadler WM, Ratain MJ. Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017764381. PMID 29590007 DOI: 10.1200/Jco.2017.76.4381 |
0.416 |
|
| 2018 |
Balasubramaniam S, Redon CE, Peer CJ, Bryla C, Lee MJ, Trepel JB, Tomita Y, Rajan A, Giaccone G, Bonner WM, Figg WD, Fojo T, Piekarz RL, Bates SE. Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung. Anti-Cancer Drugs. PMID 29420340 DOI: 10.1097/Cad.0000000000000596 |
0.383 |
|
| 2018 |
Jackson S, Weingart J, Nduom EK, Harfi TT, George RT, McAreavey D, Ye X, Anders NM, Peer C, Figg WD, Gilbert M, Rudek MA, Grossman SA. The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids and Barriers of the Cns. 15: 2. PMID 29332604 DOI: 10.1186/S12987-017-0088-8 |
0.527 |
|
| 2018 |
Kazandjian D, Korde N, Mailankody S, Zhang Y, Hsu J, Hill E, Morrison C, Divakarla S, Kwok ML, Manasanch EE, Bhutani M, Tageja N, Galera P, Dulau-Florea A, Salem D, ... ... Figg W, et al. A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up Blood. 132: 1957-1957. DOI: 10.1182/Blood-2018-99-111712 |
0.31 |
|
| 2018 |
Strope JD, Harris EM, Beedie SL, Chau CH, Cook KM, Schofield CJ, Gustafson KR, Figg WD. Abstract 14: Preclinical evaluation of novel HIF-1α/P300 binding inhibitors Cancer Research. 78: 14-14. DOI: 10.1158/1538-7445.Am2018-14 |
0.359 |
|
| 2017 |
Mailankody S, Kazandjian D, Korde N, Roschewski M, Manasanch E, Bhutani M, Tageja N, Kwok M, Zhang Y, Zingone A, Lamy L, Costello R, Morrison C, Hultcrantz M, Christofferson A, ... ... Figg WD, et al. Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. Blood Advances. 1: 1911-1918. PMID 29296837 DOI: 10.1182/Bloodadvances.2017005934 |
0.305 |
|
| 2017 |
Tang L, Platek ME, Yao S, Till C, Goodman PJ, Tangen CM, Wu Y, Platz EA, Neuhouser ML, Stanczyk FZ, Reichardt JKV, Santella RM, Hsing A, Figg WD, Lippman SM, et al. Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Carcinogenesis. PMID 29228205 DOI: 10.1093/Carcin/Bgx144 |
0.372 |
|
| 2017 |
Schmidt KT, Madan RA, Figg WD. Expanding the use of abiraterone in prostate cancer: Is earlier always better? Cancer Biology & Therapy. 1-4. PMID 29219670 DOI: 10.1080/15384047.2017.1394555 |
0.379 |
|
| 2017 |
Lee JM, Hays JL, Chiou VL, Annunziata CM, Swisher EM, Harrell MI, Yu M, Gordon N, Sissung TM, Ji J, Figg WD, Minasian L, Lipkowitz S, Wood BJ, Doroshow J, et al. Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer. Oncotarget. 8: 79175-79187. PMID 29108297 DOI: 10.18632/Oncotarget.16577 |
0.345 |
|
| 2017 |
Li M, Thapa P, Rajaputra P, Bio M, Peer CJ, Figg WD, You Y, Woo S. Quantitative modeling of the dynamics and intracellular trafficking of far-red light-activatable prodrugs: implications in stimuli-responsive drug delivery system. Journal of Pharmacokinetics and Pharmacodynamics. PMID 28913666 DOI: 10.1007/S10928-017-9543-Z |
0.324 |
|
| 2017 |
Hauke RJ, Sissung TM, Figg WD. Discussing the Predictive, Prognostic, and Therapeutic Value of Germline DNA-Repair Gene Mutations in Metastatic Prostate Cancer Patients. Cancer Biology & Therapy. 0. PMID 28678600 DOI: 10.1080/15384047.2017.1345398 |
0.404 |
|
| 2017 |
Peer CJ, Lee JM, Roth J, Rodgers L, Nguyen J, Annunziata CM, Minasian L, Kohn EC, Figg WD. Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers. Cancer Chemotherapy and Pharmacology. PMID 28577239 DOI: 10.1007/S00280-017-3346-1 |
0.365 |
|
| 2017 |
Rodgers L, Peer CJ, Figg WD. Diagnosis, Staging, and Risk Stratification in Prostate Cancer: Utilizing Diagnostic Tools to Avoid Unnecessary Therapies and Side Effects. Cancer Biology & Therapy. 0. PMID 28475407 DOI: 10.1080/15384047.2017.1323600 |
0.393 |
|
| 2017 |
Tuerff D, Sissung T, Figg WD. Cellular identity crisis: antiandrogen resistance by lineage plasticity. Cancer Biology & Therapy. 0. PMID 28475401 DOI: 10.1080/15384047.2017.1323599 |
0.384 |
|
| 2017 |
Lee JM, Cimino-Mathews A, Peer CJ, Zimmer A, Lipkowitz S, Annunziata CM, Cao L, Harrell MI, Swisher EM, Houston N, Botesteanu DA, Taube JM, Thompson E, Ogurtsova A, Xu H, ... ... Figg WD, et al. Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016721340. PMID 28471727 DOI: 10.1200/Jco.2016.72.1340 |
0.348 |
|
| 2017 |
Duffy A, Ma C, Ulahannan S, Rahma OE, Makarova-Rusher O, Cao L, Yu Y, Kleiner D, Trepel J, Lee MJ, Tomita Y, Steinberg SM, Heller T, Turkbey B, Choyke PL, ... ... Figg WD, et al. Phase I and preliminary Phase II study of TRC105 in combination with Sorafenib in Hepatocellular Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28465443 DOI: 10.1158/1078-0432.Ccr-16-3171 |
0.356 |
|
| 2017 |
Norris JD, Ellison SJ, Baker JG, Stagg DB, Wardell SE, Park S, Alley HM, Baldi RM, Yllanes A, Andreano KJ, Stice JP, Lawrence SA, Eisner JR, Price DK, Moore WR, ... Figg WD, et al. Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer. The Journal of Clinical Investigation. PMID 28463227 DOI: 10.1172/Jci87328 |
0.386 |
|
| 2017 |
Lee DK, Figg WD. A New Predictive Tool for Postoperative Radiotherapy in Prostate Cancer. Cancer Biology & Therapy. 0. PMID 28418285 DOI: 10.1080/15384047.2017.1310347 |
0.362 |
|
| 2017 |
Sissung TM, Ley AM, Strope JD, McCrea EM, Beedie SL, Peer CJ, Shukla S, van Velkinburgh JC, Reece K, Troutman S, Campbell T, Fernandez E, Huang P, Smith J, Thakkar N, ... ... Figg WD, et al. Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx. Molecular Cancer Research : McR. PMID 28389619 DOI: 10.1158/1541-7786.Mcr-16-0477 |
0.357 |
|
| 2017 |
Uldrick TS, Gonçalves PH, Wyvill KM, Peer CJ, Bernstein W, Aleman K, Polizzotto MN, Venzon D, Steinberg SM, Marshall V, Whitby D, Little RF, Wright JJ, Rudek MA, Figg WD, et al. A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma. The Oncologist. PMID 28341759 DOI: 10.1634/Theoncologist.2016-0486 |
0.573 |
|
| 2017 |
League-Pascual JC, Lester-McCully CM, Shandilya S, Ronner L, Rodgers L, Cruz R, Peer CJ, Figg WD, Warren KE. Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model. Journal of Neuro-Oncology. PMID 28290002 DOI: 10.1007/S11060-017-2388-X |
0.323 |
|
| 2017 |
Feinman HE, Price DK, Figg WD. Piecing the Puzzle Together: Docetaxel Cycles and Current Considerations in the Treatment of Metastatic Castration-Resistant Prostate Cancer. Cancer Biology & Therapy. 0. PMID 28278075 DOI: 10.1080/15384047.2017.1295192 |
0.398 |
|
| 2017 |
Duffy AG, Pratt D, Kleiner DE, Mabry D, Fioravanti S, Walker M, Figg WD, Steinberg SM, Anderson V, Krishnasamy V, Wood BJ, Greten TF. Tremelimumab: A monoclonal antibody against CTLA-4—In combination with radiofrequency ablation (RFA) in patients with biliary tract carcinoma (BTC). Journal of Clinical Oncology. 35: 316-316. DOI: 10.1200/Jco.2017.35.7_Suppl.88 |
0.322 |
|
| 2017 |
Szmulewitz RZ, Ibraheem AF, Peer CJ, Figg WD, Carthon BC, Kozloff M, Harvey D, Fishkin PAS, Yong WP, Chiong E, Nabhan C, O'Donnell PH, Stadler WM, Ratain MJ. A prospective international randomized phase II study evaluating the food effect on the pharmacokinetics (PK) and pharmacodynamics (PD) of abiraterone acetate (AA) in men with castration-resistant prostate cancer (CRPC). Journal of Clinical Oncology. 35: 176-176. DOI: 10.1200/Jco.2017.35.6_Suppl.176 |
0.362 |
|
| 2017 |
Duffy AG, Makarova-Rusher OV, Kleiner DE, Alewine C, Figg WD, Steinberg SM, Levy EB, Krishnasamy VP, Wood BJ, Citrin DE, Jones JC, Greten TF. A pilot study of immune checkpoint inhibition in combination with radiation therapy in patients with metastatic pancreatic cancer. Journal of Clinical Oncology. 35: e15786-e15786. DOI: 10.1200/Jco.2017.35.15_Suppl.E15786 |
0.339 |
|
| 2017 |
Zimmer A, Gatti-Mays ME, Lipkowitz S, Karzai F, Gulley J, Dahut W, Steinberg S, Figg WD, Madan R. Abstract CT058: A phase 2 open-label study to evaluate the efficacy and safety of VT-464 in patients with androgen receptor positive triple-negative breast cancer patients, and men with ER positive breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct058 |
0.373 |
|
| 2017 |
Tang L, Platek M, Yao S, Till C, Goodman P, Tangen CM, Wu Y, Platz EA, Neuhouse ML, Stanczyk FZ, Reichardt JK, Santella RM, Hsing A, Figg WD, Lippman SM, et al. Abstract 1274: Associations between genetic polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial Epidemiology. 77: 1274-1274. DOI: 10.1158/1538-7445.Am2017-1274 |
0.387 |
|
| 2017 |
Jackson S, Weingart J, Nduom E, Holdhoff M, Blakeley J, Piotrowski AF, Abd T, George R, McAreavey D, Ye X, Anders N, Peer C, Barnes J, Figg W, Rudek M, et al. ACTR-85. THE EFFECT OF REGADENOSON ON TEMOZOLOMIDE NEUROPHARMACOKINETICS IN GLIOBLASTOMA PATIENTS MEASURED BY INTRACEREBRAL MICRODIALYSIS Neuro-Oncology. 19: vi19-vi19. DOI: 10.1093/Neuonc/Nox168.071 |
0.507 |
|
| 2017 |
McCrea E, Huang P, Harris E, Strope J, Sissung T, Price D, Chau C, Figg W. Expression of steroid hormone transporter, SLCO1B3, is mediated by a CBP/p300 regulatory mechanism in prostate cancer Annals of Oncology. 28: v285-v286. DOI: 10.1093/Annonc/Mdx370.040 |
0.363 |
|
| 2016 |
Schmidt KT, Figg WD. The potential role of curcumin in prostate cancer: the importance of optimizing pharmacokinetics in clinical studies. Translational Cancer Research. 5: S1107-S1110. PMID 30613476 DOI: 10.21037/Tcr.2016.11.04 |
0.416 |
|
| 2016 |
Sissung TM, Deeken J, Leibrand CR, Price DK, Ehrlich S, Steinberg SM, Liewehr DJ, Dahut W, Figg WD. Identification of novel SNPs associated with risk and prognosis in patients with castration-resistant prostate cancer. Pharmacogenomics. PMID 27883295 DOI: 10.2217/Pgs-2016-0134 |
0.369 |
|
| 2016 |
Polizzotto MN, Uldrick TS, Wyvill KM, Aleman K, Peer CJ, Bevans M, Sereti I, Maldarelli F, Whitby D, Marshall V, Goncalves PH, Khetani V, Figg WD, Steinberg SM, Zeldis JB, et al. Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 4125-4131. PMID 27863194 DOI: 10.1200/Jco.2016.69.3812 |
0.303 |
|
| 2016 |
Ferraz Nogueira Filho MA, Peer CJ, Nguyen J, McCalla A, Helman L, Figg WD. A simple and rapid UHPLC-MS/MS method for the quantitation of the dual aurora kinase A/B inhibitor SCH-1473759 in murine plasma. Journal of Pharmaceutical and Biomedical Analysis. 132: 223-226. PMID 27768921 DOI: 10.1016/J.Jpba.2016.10.003 |
0.303 |
|
| 2016 |
Goey AK, Sissung TM, Peer CJ, Figg WD. Pharmacogenomics and histone deacetylase inhibitors. Pharmacogenomics. PMID 27767376 DOI: 10.2217/Pgs-2016-0113 |
0.319 |
|
| 2016 |
McCrea E, Sissung TM, Price DK, Chau CH, Figg WD. ANDROGEN RECEPTOR VARIATION AFFECTS PROSTATE CANCER PROGRESSION AND DRUG RESISTANCE. Pharmacological Research. PMID 27725309 DOI: 10.1016/J.Phrs.2016.10.001 |
0.426 |
|
| 2016 |
Manasanch EE, de Larrea CF, Zingone A, Steinberg SM, Kwok M, Tageja N, Bhutani M, Kazandjian D, Roschewski M, Wu P, Carter G, Zuchlinski D, Mulquin M, Lamping L, Costello R, ... ... Figg WD, et al. Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone. Leukemia & Lymphoma. 1-10. PMID 27687480 DOI: 10.1080/10428194.2016.1214953 |
0.324 |
|
| 2016 |
Lee JM, Peer CJ, Yu M, Amable L, Gordon N, Annunziata CM, Houston N, Goey AK, Sissung TM, Parker B, Minasian L, Chiou V, Murphy RF, Widemann BC, Figg WD, et al. Sequence-specific pharmacokinetic and pharmacodynamic phase I/Ib study of olaparib tablets and carboplatin in women's cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27663600 DOI: 10.1158/1078-0432.Ccr-16-1546 |
0.312 |
|
| 2016 |
Beedie SL, Mahony C, Walker HM, Chau CH, Figg WD, Vargesson N. Shared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model. Scientific Reports. 6: 30038. PMID 27443489 DOI: 10.1038/Srep30038 |
0.309 |
|
| 2016 |
Schmidt KT, Chau CH, Price DK, Figg WD. Precision Oncology Medicine: The Clinical Relevance of Patient Specific Biomarkers Used to Optimize Cancer Treatment. Journal of Clinical Pharmacology. PMID 27197880 DOI: 10.1002/Jcph.765 |
0.374 |
|
| 2016 |
Duffy AG, Makarova-Rusher OV, Ulahannan SV, Rahma OE, Fioravanti S, Walker M, Abdullah S, Raffeld M, Anderson V, Abi-Jaoudeh N, Levy E, Wood BJ, Lee S, Tomita Y, Trepel JB, ... ... Figg WD, et al. Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750 - an antisense oligonucleotide against eIF4E - in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer. International Journal of Cancer. PMID 27194579 DOI: 10.1002/Ijc.30199 |
0.398 |
|
| 2016 |
Price DK, Chau CH, Till C, Goodman PJ, Leach RJ, Johnson-Pais TL, Hsing AW, Hoque A, Parnes HL, Schenk JM, Tangen CM, Thompson IM, Reichardt JK, Figg WD. Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial. Cancer. PMID 27164191 DOI: 10.1002/Cncr.30071 |
0.393 |
|
| 2016 |
Leibrand CR, Price DK, Figg WD. Androgen receptor splice variant 7 (AR-V7) and drug efficacy in castration-resistant prostate cancer: Biomarker for treatment selection exclusion or inclusion? Cancer Biology & Therapy. 17: 467-9. PMID 26985596 DOI: 10.1080/15384047.2016.1156274 |
0.376 |
|
| 2016 |
Beedie S, Figg WD. Resisting resistance: Establishing new treatment options for CRPC patients. Cancer Biology & Therapy. 17: 337-8. PMID 26828765 DOI: 10.1080/15384047.2016.1139271 |
0.315 |
|
| 2016 |
Strope JD, Price DK, Figg WD. Building a hit list for the fight against metastatic castration resistant prostate cancer. Cancer Biology & Therapy. 17: 231-2. PMID 26822877 DOI: 10.1080/15384047.2016.1139270 |
0.372 |
|
| 2016 |
Madan RA, Karzai FH, Ning YM, Adesunloye BA, Huang X, Harold N, Couvillon A, Chun G, Cordes L, Sissung T, Beedie SL, Dawson NA, Theoret MR, McLeod DG, Rosner I, ... ... Figg WD, et al. Phase II Trial of Docetaxel, Bevacizumab, Lenalidomide, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer. Bju International. PMID 26780387 DOI: 10.1111/Bju.13412 |
0.419 |
|
| 2016 |
Goey AK, Figg WD. UGT genotyping in belinostat dosing. Pharmacological Research. 105: 22-7. PMID 26773202 DOI: 10.1016/J.Phrs.2016.01.002 |
0.342 |
|
| 2016 |
Duffy AG, Makarova-Rusher OV, Pratt D, Kleiner DE, Alewine C, Fioravanti S, Walker M, Carey S, Figg WD, Steinberg SM, Anderson V, Levy E, Krishnasamy V, Wood BJ, Jones J, et al. A pilot study of immune checkpoint inhibition (tremelimumab and/or MEDI4736) in combination with radiation therapy in patients with unresectable pancreatic cancer. Journal of Clinical Oncology. 34: TPS470-TPS470. DOI: 10.1200/Jco.2016.34.4_Suppl.Tps470 |
0.336 |
|
| 2016 |
Duffy AG, Makarova-Rusher OV, Pratt D, Kleiner DE, Fioravanti S, Walker M, Carey S, Figg WD, Steinberg SM, Anderson V, Levy E, Krishnasamy V, Wood BJ, Jones J, Citrin DE, et al. A pilot study of AMP-224, a PD-L2 Fc fusion protein, in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic colorectal cancer. Journal of Clinical Oncology. 34: 560-560. DOI: 10.1200/Jco.2016.34.4_Suppl.560 |
0.334 |
|
| 2016 |
Karzai F, Madan RA, Ning Y, Theoret MR, Arlen PM, Parnes HL, Ojemuyiwa MA, Strauss J, Dawson NA, McLeod DG, Harold N, Couvillon A, Cordes LM, Chen C, Steinberg SM, ... ... Figg WD, et al. Comparison of survival of African-American (AA) patients (pts) in docetaxel (D)-based combination therapies in metastatic castrate-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 34: 272-272. DOI: 10.1200/Jco.2016.34.2_Suppl.272 |
0.341 |
|
| 2016 |
Madan RA, Donahue RN, Singh H, Karzai F, Theoret MR, Heery CR, Strauss J, Harold N, Couvillon A, Marte JL, Hankin A, Grenga I, Chun G, Rosner IL, McLeod DG, ... ... Figg WD, et al. Clinical and immunologic impact of short course enzalutamide without androgen deprivation therapy for biochemically recurrent prostate cancer. Journal of Clinical Oncology. 34: 214-214. DOI: 10.1200/Jco.2016.34.2_Suppl.214 |
0.386 |
|
| 2016 |
Strauss J, Ahlman M, Karzai F, Heery CR, Cordes LM, McMahon S, Couvillon A, Rauckhorst M, Thomas C, Theoret MR, Marte JL, Millo C, Lindenberg ML, Turkbey IB, Choyke PL, ... Figg WD, et al. An analysis of sodium 18f-fluoride PET/CT and prostate specific antigen (PSA) changes in men with metastatic castration resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 34: 203-203. DOI: 10.1200/Jco.2016.34.2_Suppl.203 |
0.31 |
|
| 2016 |
Madan RA, Donahue RN, Singh H, Karzai F, Theoret MR, Heery CR, Strauss J, Harold N, Couvillon A, Marte JL, Hankin A, Grenga I, Chun G, Cordes LM, Figg WD, et al. Short course enzalutamide monotherapy in biochemically recurrent prostate cancer: Clinical and immunologic impact. Journal of Clinical Oncology. 34: e16619-e16619. DOI: 10.1200/Jco.2016.34.15_Suppl.E16619 |
0.395 |
|
| 2016 |
Kazandjian D, Korde NS, Roschewski M, Mailankody S, Morrison C, Manasanch EE, Kwok ML, Tageja N, Bhutani M, Zingone A, Costello R, Zhang Y, Mulquin M, Lamping L, Carpenter A, ... ... Figg W, et al. Sustained Minimal Residual Disease Negativity in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R): Updated Results of a Phase 2 Study Blood. 128: 4527-4527. DOI: 10.1182/Blood.V128.22.4527.4527 |
0.334 |
|
| 2016 |
Kazandjian D, Korde NS, Roschewski M, Mailankody S, Morrison C, Manasanch EE, Kwok ML, Tageja N, Bhutani M, Zingone A, Costello R, Zhang Y, Mulquin M, Lamping L, Carpenter A, ... ... Figg W, et al. Sustained High Rates of Complete Response and Minimal Residual Disease Negativity after 8 Cycles of Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R) in Patients with High-Risk Smoldering Multiple Myeloma: Updated Results of Clinical and Correlative Phase 2 Study Blood. 128: 3339-3339. DOI: 10.1182/Blood.V128.22.3339.3339 |
0.321 |
|
| 2016 |
Cao L, Karzai F, Apolo A, Madan R, Yu Y, Gulley J, Figg W, Dahut W. Abstract 2048: Pharmacodynamic biomarker studies of TRC105 anti-endoglin (CD105) antibody revealed anti-angiogenic activity associated with CD105 depletion Cancer Research. 76: 2048-2048. DOI: 10.1158/1538-7445.Am2016-2048 |
0.317 |
|
| 2016 |
Goey AKL, Peer CJ, Sissung TM, Roth J, Shahbazi S, Nguyen J, Annunziata CM, Houston N, Kohn EC, Lee J, Figg WD. Abstract 2043: Effects of 24-h carboplatin pretreatment on olaparib clearance in women's cancers using noncompartmental and population pharmacokinetic analyses Cancer Research. 76: 2043-2043. DOI: 10.1158/1538-7445.Am2016-2043 |
0.377 |
|
| 2016 |
Sissung TM, John D, Leibrand CR, Price DK, Ehrlich S, Steinberg SM, Liewehr DJ, Dahut WL, Figg WD. Abstract 1794: Identification of novel single nucleotide polymorphisms (SNPs) associated with risk and prognosis in patients with castration-resistant prostate cancer (CRPC) Cancer Research. 76: 1794-1794. DOI: 10.1158/1538-7445.Am2016-1794 |
0.32 |
|
| 2016 |
McCully CML, Rodgers L, Cruz R, Peer C, Figg WD, Warren KE. PCM-10PLASMA AND CEREBROSPINAL FLUID PHARMACOKINETICS OF 5-AZACYTIDINE FOLLOWING INTRAVENOUS, INTRANASAL, AND INTRATHECAL ADMINISTRATION IN A NON-HUMAN PRIMATE MODEL Neuro-Oncology. 18: iii141.2-iii141. DOI: 10.1093/Neuonc/Now080.10 |
0.324 |
|
| 2015 |
Peer CJ, Goey AK, Sissung TM, Erlich S, Lee MJ, Tomita Y, Trepel JB, Piekarz R, Balasubramaniam S, Bates SE, Figg WD. UGT1A1 genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation. Journal of Clinical Pharmacology. PMID 26637161 DOI: 10.1002/Jcph.627 |
0.349 |
|
| 2015 |
Schenk JM, Till C, Hsing AW, Stanczyk FZ, Gong Z, Neuhouser ML, Reichardt JK, Hoque AM, Figg WD, Goodman PJ, Tangen CM, Thompson IM. Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial. Cancer Causes & Control : Ccc. PMID 26589415 DOI: 10.1007/S10552-015-0695-0 |
0.39 |
|
| 2015 |
Polman DJ, Price DK, Figg WD. New bigenic mouse model increases the understanding of genetic synergism in the progression of prostate cancer. Cancer Biology & Therapy. 0. PMID 26552331 DOI: 10.1080/15384047.2015.1108498 |
0.364 |
|
| 2015 |
Goey AK, Sissung TM, Peer CJ, Trepel JB, Lee MJ, Tomita Y, Ehrlich S, Bryla C, Balasubramaniam S, Piekarz R, Steinberg SM, Bates SE, Figg WD. Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics and toxicities of belinostat administered by 48 h continuous infusion in patients with cancer. Journal of Clinical Pharmacology. PMID 26313268 DOI: 10.1002/Jcph.625 |
0.345 |
|
| 2015 |
Beedie SL, Peer CJ, Pisle S, Gardner ER, Mahony C, Barnett S, Ambrozak A, Gütschow M, Chau CH, Vargesson N, Figg WD. Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues. Molecular Cancer Therapeutics. 14: 2228-37. PMID 26269604 DOI: 10.1158/1535-7163.Mct-15-0320 |
0.303 |
|
| 2015 |
Figg WD, Thompson IM. Effect of 5α-Reductase Inhibitor Use on Mortality From Prostate Cancer. Jama Oncology. 1: 321-2. PMID 26181178 DOI: 10.1001/Jamaoncol.2015.0408 |
0.354 |
|
| 2015 |
Lee JM, Trepel JB, Choyke P, Cao L, Sissung T, Houston N, Yu M, Figg WD, Turkbey IB, Steinberg SM, Lee MJ, Ivy SP, Liu JF, Matulonis UA, Kohn EC. CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer. Frontiers in Oncology. 5: 123. PMID 26082895 DOI: 10.3389/Fonc.2015.00123 |
0.309 |
|
| 2015 |
Massey PR, Prasad V, Figg WD, Fojo T. Multiplying therapies and reducing toxicity in metastatic melanoma. Cancer Biology & Therapy. 16: 1014-8. PMID 26016850 DOI: 10.1080/15384047.2015.1046650 |
0.356 |
|
| 2015 |
Chau CH, Price DK, Till C, Goodman PJ, Chen X, Leach RJ, Johnson-Pais TL, Hsing AW, Hoque A, Tangen CM, Chu L, Parnes HL, Schenk JM, Reichardt JK, Thompson IM, ... Figg WD, et al. Finasteride concentrations and prostate cancer risk: results from the prostate cancer prevention trial. Plos One. 10: e0126672. PMID 25955319 DOI: 10.1371/Journal.Pone.0126672 |
0.398 |
|
| 2015 |
Karzai FH, Madan RA, Figg WD. Beyond PSA: managing modern therapeutic options in metastatic castration-resistant prostate cancer. Southern Medical Journal. 108: 224-8. PMID 25871992 DOI: 10.14423/Smj.0000000000000266 |
0.404 |
|
| 2015 |
Zalazar F, De Luca P, Gardner K, Figg WD, Meiss R, Spallanzani RG, Vallecorsa P, Elguero B, Cotignola J, Vazquez E, De Siervi A. Low doses of CPS49 and flavopiridol combination as potential treatment for advanced prostate cancer. Current Pharmaceutical Biotechnology. 16: 553-63. PMID 25860066 DOI: 10.2174/138920101606150407114407 |
0.429 |
|
| 2015 |
Fernandez EV, Reece KM, Ley AM, Troutman SM, Sissung TM, Price DK, Chau CH, Figg WD. Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells. Molecular Pharmacology. 87: 1006-12. PMID 25829060 DOI: 10.1124/Mol.114.097477 |
0.343 |
|
| 2015 |
Baird K, Comis LE, Joe GO, Steinberg SM, Hakim FT, Rose JJ, Mitchell SA, Pavletic SZ, Figg WD, Yao L, Flanders KC, Takebe N, Sarantopoulos S, Booher S, Cowen EW. Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 21: 1083-90. PMID 25771402 DOI: 10.1016/J.Bbmt.2015.03.006 |
0.313 |
|
| 2015 |
Okoli TC, Peer CJ, Dunleavy K, Figg WD. Targeted PI3Kδ inhibition by the small molecule idelalisib as a novel therapy in indolent non-Hodgkin lymphoma. Cancer Biology & Therapy. 16: 204-6. PMID 25756507 DOI: 10.1080/15384047.2014.1002369 |
0.319 |
|
| 2015 |
Hoque A, Yao S, Till C, Kristal AR, Goodman PJ, Hsing AW, Tangen CM, Platz EA, Stanczyk FZ, Reichardt JK, vanBokhoven A, Neuhouser ML, Santella RM, Figg WD, Price DK, et al. Effect of finasteride on serum androstenedione and risk of prostate cancer within the prostate cancer prevention trial: differential effect on high- and low-grade disease. Urology. 85: 616-20. PMID 25733274 DOI: 10.1016/J.Urology.2014.11.024 |
0.392 |
|
| 2015 |
Akshintala S, Marcus L, Warren KE, Murphy RF, Sissung TM, Srivastava A, Goodspeed WJ, Goodwin A, Brewer CC, Zalewski C, King KA, Kim A, Figg WD, Widemann BC. Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors. Pediatric Blood & Cancer. 62: 603-10. PMID 25556988 DOI: 10.1002/Pbc.25344 |
0.345 |
|
| 2015 |
Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo AT, Morris JC, Fleisher TA, Dubois SP, Perera LP, Stewart DM, Goldman CK, Bryant BR, Decker JM, Chen J, Worthy TA, ... Figg WD, et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 74-82. PMID 25403209 DOI: 10.1200/Jco.2014.57.3329 |
0.341 |
|
| 2015 |
Figg WD, Fernandez EV, Reece KM, Ley AM, Troutman SM, Sissung TM, Price DK, Chau CH. Dual targeting of the androgen receptor and hypoxia-inducible factor-1α pathways to synergistically inhibit castrate-resistant prostate cancer. Journal of Clinical Oncology. 33: 270-270. DOI: 10.1200/Jco.2015.33.7_Suppl.270 |
0.339 |
|
| 2015 |
Karzai F, Madan RA, Theoret MR, Arlen PM, Dawson NA, Rosner IL, McLeod DG, Wright JJ, Cordes LM, Couvillon A, Chun G, Harold N, Steinberg SM, Trepel JB, Price DK, ... ... Figg WD, et al. Cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 33: 235-235. DOI: 10.1200/Jco.2015.33.7_Suppl.235 |
0.368 |
|
| 2015 |
Makarova-Rusher OV, Duffy AG, Ulahannan SV, Fioravanti S, Walker M, Raffeld M, Compton K, Lee S, Tomita Y, Trepel JB, Figg WD, Greten TF. Phase I/II study of ISIS 183750 in combination with irinotecan for advanced solid tumors or colorectal cancer: Final results. Journal of Clinical Oncology. 33: 639-639. DOI: 10.1200/Jco.2015.33.3_Suppl.639 |
0.361 |
|
| 2015 |
Karzai F, Madan RA, Theoret MR, Arlen PM, Strauss J, Chun G, Couvillon A, Harold N, Chen C, Dawson NA, Apolo AB, Steinberg SM, Trepel JB, Wright JJ, Price DK, ... ... Figg WD, et al. Overcoming resistance mechanisms in a study of cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E16032 |
0.335 |
|
| 2015 |
Goey AK, Trepel JB, Sissung TM, Peer CJ, Lee M, Tomita Y, Ehrlich S, Bryla C, Berman AW, Balasubramaniam S, Piekarz R, Rajan A, Steinberg SM, Giaccone G, Figg WD, et al. UGT1A1 genotype effects on PK, PD and toxicities of belinostat administered by 48 h continuous infusion. Journal of Clinical Oncology. 33: e13581-e13581. DOI: 10.1200/Jco.2015.33.15_Suppl.E13581 |
0.353 |
|
| 2015 |
Goey AKL, Sissung TM, Peer CJ, Ehrlich S, Bryla C, Berman AW, Balasubramaniam S, Rajan A, Giaccone G, Bates SE, Figg WD. Abstract 5480: Effects of UGT1A1 genotype on pharmacokinetics and toxicities of belinostat administered by continuous infusion in two clinical trials Cancer Research. 75: 5480-5480. DOI: 10.1158/1538-7445.Am2015-5480 |
0.33 |
|
| 2015 |
O'Sullivan CC, Lindenberg M, Bryla C, Davarpanah N, Peer C, Patronas N, Amiri-Kordestani L, Balasubramaniam S, Fojo T, Figg WD, Choyke P. Abstract B43: ANG1005, a novel brain-penetrant drug conjugate, in CNS metastases from breast cancer: FLT-PET imaging as a predictor of response Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B43 |
0.334 |
|
| 2014 |
Lochrin SE, Price DK, Figg WD. BET bromodomain inhibitors--a novel epigenetic approach in castration-resistant prostate cancer. Cancer Biology & Therapy. 15: 1583-5. PMID 25535892 DOI: 10.4161/15384047.2014.962297 |
0.387 |
|
| 2014 |
Johnson LM, Choyke PL, Figg WD, Turkbey B. The role of MRI in prostate cancer active surveillance. Biomed Research International. 2014: 203906. PMID 25525592 DOI: 10.1155/2014/203906 |
0.41 |
|
| 2014 |
Karzai FH, Apolo AB, Cao L, Madan RA, Adelberg DE, Parnes H, McLeod DG, Harold N, Peer C, Yu Y, Tomita Y, Lee MJ, Lee S, Trepel JB, Gulley JL, ... Figg WD, et al. A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer. Bju International. PMID 25407442 DOI: 10.1111/Bju.12986 |
0.365 |
|
| 2014 |
Blumenthal GM, Gills JJ, Ballas MS, Bernstein WB, Komiya T, Dechowdhury R, Morrow B, Root H, Chun G, Helsabeck C, Steinberg SM, LoPiccolo J, Kawabata S, Gardner ER, Figg WD, et al. A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors. Oncotarget. 5: 8161-72. PMID 25327558 DOI: 10.18632/Oncotarget.2415 |
0.376 |
|
| 2014 |
Gordon MS, Robert F, Matei D, Mendelson DS, Goldman JW, Chiorean EG, Strother RM, Seon BK, Figg WD, Peer CJ, Alvarez D, Adams BJ, Theuer CP, Rosen LS. An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5918-26. PMID 25261556 DOI: 10.1158/1078-0432.Ccr-14-1143 |
0.318 |
|
| 2014 |
Holkova B, Kmieciak M, Perkins EB, Bose P, Baz RC, Roodman GD, Stuart RK, Ramakrishnan V, Wan W, Peer CJ, Dawson J, Kang L, Honeycutt C, Tombes MB, Shrader E, ... ... Figg WD, et al. Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5652-62. PMID 25248382 DOI: 10.1158/1078-0432.Ccr-14-0805 |
0.32 |
|
| 2014 |
Roth J, Peer CJ, Widemann B, Cole DE, Ershler R, Helman L, Schrump D, Figg WD. Quantitative determination of mithramycin in human plasma by a novel, sensitive ultra-HPLC-MS/MS method for clinical pharmacokinetic application. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 970: 95-101. PMID 25247492 DOI: 10.1016/J.Jchromb.2014.08.021 |
0.318 |
|
| 2014 |
Sissung TM, Price DK, Del Re M, Ley AM, Giovannetti E, Figg WD, Danesi R. Genetic variation: effect on prostate cancer. Biochimica Et Biophysica Acta. 1846: 446-56. PMID 25199985 DOI: 10.1016/J.Bbcan.2014.08.007 |
0.416 |
|
| 2014 |
Thomas A, Rajan A, Szabo E, Tomita Y, Carter CA, Scepura B, Lopez-Chavez A, Lee MJ, Redon CE, Frosch A, Peer CJ, Chen Y, Piekarz R, Steinberg SM, Trepel JB, ... Figg WD, et al. A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5392-402. PMID 25189481 DOI: 10.1158/1078-0432.Ccr-14-0968 |
0.341 |
|
| 2014 |
Goey AK, Figg WD. Potential novel role of bevacizumab in glioblastoma and cervical cancer. Cancer Biology & Therapy. 15: 1296-8. PMID 25046485 DOI: 10.4161/Cbt.29926 |
0.368 |
|
| 2014 |
Srivastava A, Price DK, Figg WD. Prostate tumor development and androgen receptor function alterations in a new mouse model with ERG overexpression and PTEN inactivation. Cancer Biology & Therapy. 15: 1293-5. PMID 25007053 DOI: 10.4161/Cbt.29694 |
0.38 |
|
| 2014 |
Shahbazi S, Peer CJ, Figg WD. Prolonged low intensity EPOCH-rituximab has improved toxicity in Burkitt lymphoma compared with standard short, high intensity therapy. Cancer Biology & Therapy. 15: 1117-9. PMID 24919059 DOI: 10.4161/Cbt.29504 |
0.31 |
|
| 2014 |
Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA, Yu M, Gordon N, Ji J, Sissung TM, Figg WD, Azad N, Wood BJ, Doroshow J, Kohn EC. Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. Journal of the National Cancer Institute. 106: dju089. PMID 24842883 DOI: 10.1093/Jnci/Dju089 |
0.32 |
|
| 2014 |
Johnson LM, Turkbey B, Figg WD, Choyke PL. Multiparametric MRI in prostate cancer management. Nature Reviews. Clinical Oncology. 11: 346-53. PMID 24840072 DOI: 10.1038/Nrclinonc.2014.69 |
0.324 |
|
| 2014 |
Figg WD, Newell DR. Pharmacologic biomarkers in the development of stratified cancer medicine. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2525-9. PMID 24831275 DOI: 10.1158/1078-0432.Ccr-14-0511 |
0.33 |
|
| 2014 |
Figg WD, Chau CH, Price DK, Till C, Goodman PJ, Cho Y, Varella-Garcia M, Reichardt JK, Tangen CM, Leach RJ, van Bokhoven A, Thompson IM, Lucia MS. Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results From the Prostate Cancer Prevention Trial. Urology. 84: 127-31. PMID 24824408 DOI: 10.1016/J.Urology.2014.03.015 |
0.394 |
|
| 2014 |
Reece KM, Richardson ED, Cook KM, Campbell TJ, Pisle ST, Holly AJ, Venzon DJ, Liewehr DJ, Chau CH, Price DK, Figg WD. Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer. Molecular Cancer. 13: 91. PMID 24775564 DOI: 10.1186/1476-4598-13-91 |
0.355 |
|
| 2014 |
Johnson LM, Rothwax JT, Turkbey B, Rais-Bahrami S, Wood BJ, Figg WD, Choyke PL, Merino MJ, Pinto PA. Multiparametric magnetic resonance imaging of the prostate aids detect lesion progression. Journal of Computer Assisted Tomography. 38: 565-7. PMID 24733004 DOI: 10.1097/Rct.0000000000000069 |
0.327 |
|
| 2014 |
Platz EA, Tangen CM, Goodman PJ, Till C, Parnes HL, Figg WD, Albanes D, Neuhouser ML, Klein EA, Lucia MS, Thompson IM, Kristal AR. Statin drug use is not associated with prostate cancer risk in men who are regularly screened. The Journal of Urology. 192: 379-84. PMID 24518774 DOI: 10.1016/J.Juro.2014.01.095 |
0.389 |
|
| 2014 |
Roth JE, Peer CJ, Price DK, Figg WD. The androgen receptor transcriptional program in castration-resistant prostate cancer: cell lines vs. tissue samples. Cancer Biology & Therapy. 15: 16-8. PMID 24253417 DOI: 10.4161/Cbt.27149 |
0.355 |
|
| 2014 |
Vaishampayan UN, Fontana J, Heilbrun LK, Smith D, Heath E, Dickow B, Figg WD. Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer. Urologic Oncology. 32: 31.e25-33. PMID 23433892 DOI: 10.1016/J.Urolonc.2012.11.017 |
0.417 |
|
| 2014 |
Shah AA, Figg W, Dahut W. Challenges in overcoming hormonal resistance in prostate cancer Clinical Investigation. 4: 153-162. DOI: 10.4155/Cli.13.131 |
0.389 |
|
| 2014 |
Roth J, Peer C, Mannargudi B, Swaisland H, Lee J, Kohn E, Figg W. A Sensitive and Robust Ultra HPLC Assay with Tandem Mass Spectrometric Detection for the Quantitation of the PARP Inhibitor Olaparib (AZD2281) in Human Plasma for Pharmacokinetic Application Chromatography. 1: 82-95. DOI: 10.3390/Chromatography1020082 |
0.326 |
|
| 2014 |
Karzai FH, Shah AA, Ojemuyiwa MA, Madan RA, Apolo AB, Dawson NA, Arlen PM, Theoret MR, Wright JJ, Chen C, Trepel JB, Couvillon A, Chun G, Harold N, Steinberg SM, ... ... Figg WD, et al. A phase I study of the multikinase inhibitor cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 32: 108-108. DOI: 10.1200/Jco.2014.32.4_Suppl.108 |
0.372 |
|
| 2014 |
Duffy AG, Ma C, Ulahannan SV, Fioravanti S, Venkatesan A, Turkbey IB, Choyke PL, Trepel JB, Cao L, Compton K, Figg WD, Greten TF. TRC105 for the treatment of hepatocellular carcinoma: Preclinical data and preliminary results from two clinical trials evaluating monotherapy and combination with sorafenib. Journal of Clinical Oncology. 32: 211-211. DOI: 10.1200/Jco.2014.32.3_Suppl.211 |
0.328 |
|
| 2014 |
Swartz C, Recio L, Phillips S, Maynor T, Figg WD. Development of a CYP1B1*3 genotyping assay and mechanism of action studies related to docetaxel treatment in CRPC. Journal of Clinical Oncology. 32: e16036-e16036. DOI: 10.1200/Jco.2014.32.15_Suppl.E16036 |
0.395 |
|
| 2014 |
Apolo AB, Parnes HL, Madan RA, Gulley JL, Trepel JB, Lee M, Lee S, Steinberg SM, John S, Velasco SVA, Figg WD, Dahut WL. A phase I study of gemcitabine, carboplatin, and lenalidomide for treatment of patients with advanced/metastatic urothelial carcinoma (UC) and other solid tumors. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.E15527 |
0.353 |
|
| 2014 |
Shah AA, Karzai F, Madan RA, Figg WD, Chau CH, Gulley JL, Chun G, Wright JJ, Apolo AB, Parnes HL, Dahut WL. A phase II study of trebananib (AMG 386) and abiraterone in metastatic castration resistant prostate cancer. Journal of Clinical Oncology. 32: 5074-5074. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps5102 |
0.437 |
|
| 2014 |
Landgren O, Roschewski M, Mailankody S, Kwok M, Manasanch EE, Bhutani M, Tageja N, Kazandjian D, Zingone A, Costello R, Burton D, Zhang Y, Wu P, Carter G, Mulquin M, ... ... Figg WD, et al. Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: Final Results from the NCI Phase 2 Pilot Study Blood. 124: 4746-4746. DOI: 10.1182/Blood.V124.21.4746.4746 |
0.308 |
|
| 2014 |
Tristan SM, Peer CJ, Korde N, Nehal L, Sham M, Landgren O, Figg WD. Plasma Protease-Mediated Metabolism of Carfilzomib and Its Implications on Clinical Effects and Side Effects Blood. 124: 3476-3476. DOI: 10.1182/Blood.V124.21.3476.3476 |
0.349 |
|
| 2014 |
Korde N, Dosani T, Simakova O, Mailankody S, Costello R, Roschewski M, Yuan C, Stetler-Stevenson M, Figg WD, Landgren O, Maric I. Biomarker Proteasome Levels Predict Response to Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients Blood. 124: 2080-2080. DOI: 10.1182/Blood.V124.21.2080.2080 |
0.322 |
|
| 2014 |
Fernandez E, Mistry H, Brightman F, Orrell D, Dahut WL, Figg WD, Stein WD, Chassagnole C. Abstract 366: Translational modeling of docetaxel-thalidomide combination treatment in metastatic, castrate-resistant prostate cancer: predicting clinical response using preclinical data Cancer Research. 74: 366-366. DOI: 10.1158/1538-7445.Am2014-366 |
0.407 |
|
| 2014 |
Conlon KC, Lugli E, Rosenberg SA, Morris JC, Fleisher T, Welles H, Dubois S, Perera L, Goldman C, Bryant B, Decker J, Shih J, Worthy T, Figg W, Peer C, et al. Abstract 2575: Results from the first-in-human phase I trials of recombinant human Interleukin 15 (rhIL-15) administered as a daily 30 minute intravenous infusion (IVB) for 12 consecutive days or as continuous intravenous infusion (CIV) for 240 hours in patients with refractory metastatic cancers Cancer Research. 74: 2575-2575. DOI: 10.1158/1538-7445.Am2014-2575 |
0.391 |
|
| 2014 |
Jochems C, Boyerinas B, Madan RA, Poole DJ, Ning Y, Figg WD, Liewehr DJ, Steinberg SM, Gulley JL, Tsang K, Schlom J. Abstract 2546: Analysis of immune cell subsets in a multidrug therapeutic regimen for patients with metastatic castration-resistant prostate cancer Cancer Research. 74: 2546-2546. DOI: 10.1158/1538-7445.Am2014-2546 |
0.383 |
|
| 2014 |
Price DK, Chau CH, Figg WD, Till CA, Goodman PJ, Cho Y, Garcia M, Reichardt J, Tangen CM, Leach RJ, Bokhoven Av, Kristal AR, Thompson IM, Lucia MS. Abstract 1863: Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results from the Prostate Cancer Prevention Trial Cancer Research. 74: 1863-1863. DOI: 10.1158/1538-7445.Am2014-1863 |
0.395 |
|
| 2013 |
Lee YH, Cecchi F, Agarwal PK, Parnes HL, Khadar K, Summerell A, Gulley JL, Compton K, Figg WD, Dahut WL, Bottaro DP. Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 314. PMID 28136967 DOI: 10.1200/Jco.2013.31.15_Suppl.4543 |
0.348 |
|
| 2013 |
Adesunloye B, Ning YM, Madan RA, Gulley JL, Apolo AB, Beatson MA, Couvillon A, Harold N, Parnes HL, Arlen PM, Wright JJ, Chen C, Dawson NA, Figg WD, Dahut WL. Use of supportive measures to improve outcome and decrease toxicity in docetaxel-based antiangiogenesis combinations. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 128. PMID 28136795 DOI: 10.1200/Jco.2013.31.6_Suppl.128 |
0.314 |
|
| 2013 |
Prager AJ, Peng CR, Lita E, McNally D, Kaushal A, Sproull M, Compton K, Dahut WL, Figg WD, Citrin D, Camphausen KA. Urinary aHGF, IGFBP3 and OPN as diagnostic and prognostic biomarkers for prostate cancer. Biomarkers in Medicine. 7: 831-41. PMID 24266816 DOI: 10.2217/Bmm.13.112 |
0.361 |
|
| 2013 |
Peer CJ, Brown JL, Martin TJ, Roth J, Spencer SD, Brassil P, McNeill KA, Kreisl TN, Fine HA, Figg WD. A novel uHPLC-MS/MS method for the quantitation of AZD7451 (AZ12607092) in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 942: 107-12. PMID 24239935 DOI: 10.1016/J.Jchromb.2013.10.023 |
0.336 |
|
| 2013 |
Fernández EV, Price DK, Figg WD. Prostate cancer progression attributed to autonomic nerve development: potential for therapeutic prevention of localized and metastatic disease. Cancer Biology & Therapy. 14: 1005-6. PMID 24025357 DOI: 10.4161/Cbt.26339 |
0.361 |
|
| 2013 |
Martin TJ, Peer CJ, Figg WD. Uncovering the genetic landscape driving castration-resistant prostate cancer. Cancer Biology & Therapy. 14: 399-400. PMID 23917376 DOI: 10.4161/Cbt.24426 |
0.365 |
|
| 2013 |
Kelly RJ, Thomas A, Rajan A, Chun G, Lopez-Chavez A, Szabo E, Spencer S, Carter CA, Guha U, Khozin S, Poondru S, Van Sant C, Keating A, Steinberg SM, Figg W, et al. A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 2601-6. PMID 23857959 DOI: 10.1093/Annonc/Mdt249 |
0.323 |
|
| 2013 |
Amiri-Kordestani L, Luchenko V, Peer CJ, Ghafourian K, Reynolds J, Draper D, Frye R, Woo S, Venzon D, Wright J, Skarulis M, Figg WD, Fojo T, Bates SE, Piekarz RL. Phase I trial of a new schedule of romidepsin in patients with advanced cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 4499-507. PMID 23757352 DOI: 10.1158/1078-0432.Ccr-13-0095 |
0.365 |
|
| 2013 |
Figg WD, Chau CH, Madan RA, Gulley JL, Gao R, Sissung TM, Spencer S, Beatson M, Aragon-Ching J, Steinberg SM, Dahut WL. Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity. Clinical Genitourinary Cancer. 11: 229-37. PMID 23684781 DOI: 10.1016/J.Clgc.2013.04.007 |
0.376 |
|
| 2013 |
Dahut WL, Madan RA, Karakunnel JJ, Adelberg D, Gulley JL, Turkbey IB, Chau CH, Spencer SD, Mulquin M, Wright J, Parnes HL, Steinberg SM, Choyke PL, Figg WD. Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. Bju International. 111: 1269-80. PMID 23419134 DOI: 10.1111/J.1464-410X.2012.11667.X |
0.427 |
|
| 2013 |
Neuhouser ML, Platz EA, Till C, Tangen CM, Goodman PJ, Kristal A, Parnes HL, Tao Y, Figg WD, Lucia MS, Hoque A, Hsing AW, Thompson IM, Pollak M. Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the prostate cancer prevention trial. Cancer Prevention Research (Philadelphia, Pa.). 6: 91-9. PMID 23315596 DOI: 10.1158/1940-6207.Capr-12-0250 |
0.382 |
|
| 2013 |
Johnson LM, Price DK, Figg WD. Treatment-induced secretion of WNT16B promotes tumor growth and acquired resistance to chemotherapy: implications for potential use of inhibitors in cancer treatment. Cancer Biology & Therapy. 14: 90-1. PMID 23114711 DOI: 10.4161/Cbt.22636 |
0.337 |
|
| 2013 |
Hall C, Troutman SM, Price DK, Figg WD, Kang MH. Bcl-2 family of proteins as therapeutic targets in genitourinary neoplasms. Clinical Genitourinary Cancer. 11: 10-9. PMID 23083798 DOI: 10.1016/J.Clgc.2012.09.002 |
0.347 |
|
| 2013 |
Gordon MS, Rosen LS, Mendelson D, Ramanathan RK, Goldman J, Liu L, Xu Y, Gerson SL, Anthony SP, Figg WD, Spencer S, Adams BJ, Theuer CP, Leigh BR, Weiss GJ. A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors. Investigational New Drugs. 31: 714-23. PMID 23054206 DOI: 10.1007/S10637-012-9876-9 |
0.345 |
|
| 2013 |
Gulley JL, Figg WD, Dahut W. Even more cost savings? Journal of Oncology Practice. 2: 202. PMID 20859336 DOI: 10.1200/Jop.2006.2.4.202 |
0.396 |
|
| 2013 |
Baksh CA, Edelman MJ, Sausville EA, Figg WD, Zhu H, Bauer KS. Population Pharmacokinetics of UCN-01 Journal of Cancer Therapy. 4: 1513-1519. DOI: 10.4236/Jct.2013.410183 |
0.334 |
|
| 2013 |
Karzai FH, Madan RA, Apolo AB, Parnes HL, Wright JJ, Trepel JB, Beatson MA, Harold N, Couvillon A, Steinberg SM, Price DK, Gulley JL, Figg WD, Dahut WL. A phase I study of cabozantinib (Cabo) plus docetaxel (D) and prednisone (P) in metastatic castrate resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 31: 5072-5072. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps5095 |
0.36 |
|
| 2013 |
Apolo AB, Parnes HL, Madan RA, Gulley JL, Wright JJ, Khadar K, Trepel JB, Schlom J, Arlen PM, Merino M, Steinberg SM, Choyke PL, Lindenberg ML, Kurdziel KA, Folio L, ... Figg WD, et al. A phase II study of cabozantinib (XL184) in patients with advanced/metastatic urothelial carcinoma. Journal of Clinical Oncology. 31: TPS4589-TPS4589. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps4589 |
0.377 |
|
| 2013 |
Karzai FH, Madan RA, Apolo AB, Ning YM, Parnes HL, Arlen PM, Beatson MA, Harold N, Couvillon A, Wright JJ, Chen C, Dawson NA, Gulley JL, Figg WD, Dahut WL. Use of supportive measures to improve outcome and decrease toxicity in docetaxel-based antiangiogenesis combinations in metastatic castrate resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.E16017 |
0.306 |
|
| 2013 |
Balasubramaniam S, Bryla C, Redon CE, Lee M, Peer C, Trepel JB, Rajan A, Bonner W, Figg WD, Fojo AT, Piekarz R, Giaccone G, Bates SE. Phase I trial of belinostat in combination with cisplatin (Cis) and etoposide (Etop). Journal of Clinical Oncology. 31: 2527-2527. DOI: 10.1200/Jco.2013.31.15_Suppl.2527 |
0.315 |
|
| 2012 |
Sissung T, Kirkland CT, Reece KM, Arnold JT, Figg WD. Effect of thalidomide on the TGFβ-1-mediated synthesis of testosterone from DHEA in prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 141. PMID 27968268 DOI: 10.1200/Jco.2012.30.5_Suppl.141 |
0.392 |
|
| 2012 |
Reece KM, Troutman SM, Pressler HM, Pisle ST, Figg WD. Androgen receptor and HIF-1α interaction in prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 197. PMID 27968134 DOI: 10.1200/Jco.2012.30.5_Suppl.197 |
0.403 |
|
| 2012 |
Adesunloye B, Huang X, Ning YM, Madan RA, Gulley JL, Beatson M, Kluetz PG, Adelberg D, Arlen PM, Parnes HL, Mulquin M, Steinberg SM, Wright JJ, Trepel JB, Dawson NA, ... ... Figg WD, et al. Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 207. PMID 27967940 DOI: 10.1200/Jco.2012.30.5_Suppl.207 |
0.385 |
|
| 2012 |
Pisle ST, Pressler HM, Troutman SM, Eisner JR, Rafferty SW, Schotzinger RJ, Moore WR, Figg WD. Activity of VT-464, a selective CYP17 lyase inhibitor, in the LNCaP prostate cancer xenograft model. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 64. PMID 27967896 DOI: 10.1200/Jco.2012.30.5_Suppl.64 |
0.405 |
|
| 2012 |
Troutman SM, Sissung TM, Cropp CD, Venzon DJ, Spencer SD, Price DK, Figg WD. Association between variants on 8q24 and prostate cancer: A review and meta-analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 28. PMID 27967851 DOI: 10.1200/Jco.2012.30.5_Suppl.28 |
0.35 |
|
| 2012 |
Pratt E, Sissung TM, Figg WD. Loss of OATP1B3 function causes Rotor syndrome: implications for potential use of inhibitors in cancer. Cancer Biology & Therapy. 13: 1374-5. PMID 22954695 DOI: 10.4161/Cbt.22010 |
0.414 |
|
| 2012 |
Kristal AR, Till C, Tangen CM, Goodman PJ, Neuhouser ML, Stanczyk FZ, Chu LW, Patel SK, Thompson IM, Reichardt JK, Hoque A, Platz EA, Figg WD, Van Bokhoven A, Lippman SM, et al. Associations of serum sex steroid hormone and 5α-androstane-3α,17β-diol glucuronide concentrations with prostate cancer risk among men treated with finasteride. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 21: 1823-32. PMID 22879203 DOI: 10.1158/1055-9965.Epi-12-0695 |
0.368 |
|
| 2012 |
Chau CH, Figg WD. Aflibercept in pediatric solid tumors: moving beyond the trap. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 4868-71. PMID 22869868 DOI: 10.1158/1078-0432.Ccr-12-2212 |
0.316 |
|
| 2012 |
Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, Figg WD, Spencer S, Adams BJ, Alvarez D, Seon BK, Theuer CP, Leigh BR, Gordon MS. A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 4820-9. PMID 22767667 DOI: 10.1158/1078-0432.Ccr-12-0098 |
0.314 |
|
| 2012 |
Huang X, Chau CH, Figg WD. Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures. Journal of Hematology & Oncology. 5: 35. PMID 22747660 DOI: 10.1186/1756-8722-5-35 |
0.375 |
|
| 2012 |
Chau CH, Figg WD. Angiogenesis inhibitors increase tumor stem cells. Cancer Biology & Therapy. 13: 586-7. PMID 22441817 DOI: 10.4161/Cbt.19852 |
0.321 |
|
| 2012 |
Rajan A, Carter CA, Kelly RJ, Gutierrez M, Kummar S, Szabo E, Yancey MA, Ji J, Mannargudi B, Woo S, Spencer S, Figg WD, Giaccone G. A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 2344-51. PMID 22371451 DOI: 10.1158/1078-0432.Ccr-11-2425 |
0.312 |
|
| 2012 |
Richardson ED, Price DK, Figg WD. Significant addition to treatment options for bone metastasis in prostate cancer. Cancer Biology & Therapy. 13: 69-70. PMID 22336908 DOI: 10.4161/Cbt.13.2.18441 |
0.364 |
|
| 2012 |
Campbell TJ, Tindall DJ, Figg WD. Dihydrotestosterone synthesis from adrenal precursors does not involve testosterone in castration-resistant prostate cancer. Cancer Biology & Therapy. 13: 237-8. PMID 22336886 DOI: 10.4161/Cbt.19608 |
0.409 |
|
| 2012 |
Gardner ER, Kelly M, Springman E, Lee KJ, Li H, Moore W, Figg WD. Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab. Investigational New Drugs. 30: 90-7. PMID 20820910 DOI: 10.1007/S10637-010-9520-5 |
0.318 |
|
| 2012 |
Figg WD, Spencer SD, Pisle ST, Pressler HM, Troutman SM, Eisner JR, Rafferty SW, Schotzinger RJ, Moore WR. Activity of oral VT-464, a selective CYP17-lyase inhibitor, in the LNCaP prostate cancer xenograft. Journal of Clinical Oncology. 30: 4671-4671. DOI: 10.1200/Jco.2012.30.15_Suppl.4671 |
0.391 |
|
| 2012 |
Adesunloye B, Huang X, Ning YM, Madan RA, Gulley JL, Beatson M, Kluetz PG, Adelberg DE, Arlen PM, Parnes HL, Mulquin M, Steinberg SM, Wright JJ, Trepel JB, Dawson NA, ... ... Figg WD, et al. Dual antiangiogenic therapy using lenalidomide and bevacizumab with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 30: 4569-4569. DOI: 10.1200/Jco.2012.30.15_Suppl.4569 |
0.33 |
|
| 2012 |
Spencer SD, Figg WD, Rosen LS, Gordon MS, Hurwitz H, Wong MK, Goldman JW, Mendelson DS, Adams BJ, Alvarez D, Seon BK, Theuer CP, Leigh BR. Dose-specific clearance of TRC105 (anti-CD105 antibody) in advanced solid tumor patients. Journal of Clinical Oncology. 30: 3042-3042. DOI: 10.1200/Jco.2012.30.15_Suppl.3042 |
0.322 |
|
| 2012 |
Karzai FH, Apolo AB, Adelberg DE, Madan RA, Gulley JL, Arlen PM, Parnes HL, Pierpoint A, Kohler DR, Price DK, Steinberg SM, Trepel JB, Figg WD, Dahut WL. A phase I study of TRC105 (anti-CD105 [endoglin] antibody) in metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 30: 117-117. DOI: 10.1200/Jco.2011.29.7_Suppl.171 |
0.388 |
|
| 2012 |
Price DK, Troutman SM, Sissung TM, Cropp C, Venzon DJ, Spencer SD, Figg WD. Abstract B29: A meta-analysis of racial disparities in the association between 8q24 and prostate cancer risk Cancer Research. 72: B29-B29. DOI: 10.1158/1538-7445.Prca2012-B29 |
0.352 |
|
| 2012 |
Jochems C, Tucker JA, Poole DJ, Beatson M, Mulquin M, Madan RA, Figg WD, Dahut WL, Gulley JL, Schlom J, Tsang K. Abstract 5379: Combination treatment with Bevacizumab, Lenalidomide, Docetaxel and Prednisone (ART-P) does not impact the immune response in patients with metastatic castration-resistant prostate cancer Cancer Research. 72: 5379-5379. DOI: 10.1158/1538-7445.Am2012-5379 |
0.37 |
|
| 2012 |
Zalazar F, Luca PD, Elguero B, Gardner K, Figg WD, Meiss R, Moiola CP, Cotignola J, Vazquez ES, Siervi AD. Abstract 2340: CPS49 and Flavopiridol: a new selective drug combination for advanced prostate cancer Cancer Research. 72: 2340-2340. DOI: 10.1158/1538-7445.Am2012-2340 |
0.445 |
|
| 2012 |
Richardson ED, Reece KM, Campbell TJ, Pressler H, Pisle ST, Figg WD. Abstract 2331: Select epidithiodiketopiperazine (ETP) compounds disrupt the HIF-1α/p300 interaction and HIF-mediated transcription Cancer Research. 72: 2331-2331. DOI: 10.1158/1538-7445.Am2012-2331 |
0.303 |
|
| 2012 |
Price DK, Reece KM, Troutman SM, Pressler HM, Pisle ST, Figg WD. Abstract 2206: Molecular interaction of HIF-1α and the androgen receptor in prostate cancer Cancer Research. 72: 2206-2206. DOI: 10.1158/1538-7445.Am2012-2206 |
0.347 |
|
| 2012 |
Pressler HM, Sissung TM, Price DK, Figg WD. Abstract 1848: Expression of an androgen transporter, organic anion transporting polypeptide 1B3, impacts progression and treatment of prostate cancer Cancer Research. 72: 1848-1848. DOI: 10.1158/1538-7445.Am2012-1848 |
0.397 |
|
| 2011 |
Rajan A, Kelly RJ, Trepel JB, Kim YS, Alarcon SV, Kummar S, Gutierrez M, Crandon S, Zein WM, Jain L, Mannargudi B, Figg WD, Houk BE, Shnaidman M, Brega N, et al. A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6831-9. PMID 21908572 DOI: 10.1158/1078-0432.Ccr-11-0821 |
0.333 |
|
| 2011 |
Sissung T, Pressler H, Price D, Figg W. SLCO Transport Genes in Prostate Cancer—Letter Cancer Epidemiology, Biomarkers & Prevention. 20: 2325-2325. PMID 21896883 DOI: 10.1158/1055-9965.Epi-11-0606 |
0.382 |
|
| 2011 |
Marti GE, Stetler-Stevenson M, Grant ND, White T, Figg WD, Tohnya T, Jaffe ES, Dunleavy K, Janik JE, Steinberg SM, Wilson WH. Phase I trial of 7-hydroxystaurosporine and fludararbine phosphate: in vivo evidence of 7-hydroxystaurosporine induced apoptosis in chronic lymphocytic leukemia. Leukemia & Lymphoma. 52: 2284-92. PMID 21745173 DOI: 10.3109/10428194.2011.589547 |
0.338 |
|
| 2011 |
Yao S, Till C, Kristal AR, Goodman PJ, Hsing AW, Tangen CM, Platz EA, Stanczyk FZ, Reichardt JK, Tang L, Neuhouser ML, Santella RM, Figg WD, Price DK, Parnes HL, et al. Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study. Cancer Causes & Control : Ccc. 22: 1121-31. PMID 21667068 DOI: 10.1007/S10552-011-9787-7 |
0.383 |
|
| 2011 |
Pressler H, Sissung TM, Venzon D, Price DK, Figg WD. Expression of OATP family members in hormone-related cancers: potential markers of progression. Plos One. 6: e20372. PMID 21625523 DOI: 10.1371/Journal.Pone.0020372 |
0.375 |
|
| 2011 |
Yang M, Xie W, Mostaghel E, Nakabayashi M, Werner L, Sun T, Pomerantz M, Freedman M, Ross R, Regan M, Sharifi N, Figg WD, Balk S, Brown M, Taplin ME, et al. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2565-73. PMID 21606417 DOI: 10.1200/Jco.2010.31.2405 |
0.398 |
|
| 2011 |
Holkova B, Perkins EB, Ramakrishnan V, Tombes MB, Shrader E, Talreja N, Wellons MD, Hogan KT, Roodman GD, Coppola D, Kang L, Dawson J, Stuart RK, Peer C, Figg WD, et al. Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 3388-97. PMID 21447728 DOI: 10.1158/1078-0432.Ccr-10-2876 |
0.317 |
|
| 2011 |
Stein WD, Gulley JL, Schlom J, Madan RA, Dahut W, Figg WD, Ning YM, Arlen PM, Price D, Bates SE, Fojo T. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 907-17. PMID 21106727 DOI: 10.1200/Jco.2012.30.5_Suppl.133 |
0.393 |
|
| 2011 |
Kelly RJ, Draper D, Chen CC, Robey RW, Figg WD, Piekarz RL, Chen X, Gardner ER, Balis FM, Venkatesan AM, Steinberg SM, Fojo T, Bates SE. A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 569-80. PMID 21081657 DOI: 10.1158/1078-0432.Ccr-10-1725 |
0.342 |
|
| 2011 |
Scripture CD, Figg WD, Sparreboom A. Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy. Therapeutics and Clinical Risk Management. 1: 107-14. PMID 18360550 DOI: 10.2147/Tcrm.1.2.107.62910 |
0.37 |
|
| 2011 |
Porter-Gill P, Fu Y, Kaushiva A, Price D, Dahut W, Figg W, Prokunina-Olsson L. Detection of bladder, breast and prostate cancer using serum and tissue miRNA profiling Genome Biology. 12: P18. DOI: 10.1186/Gb-2011-12-S1-P18 |
0.314 |
|
| 2011 |
Porter-Gill PA, Fu Y, Kaushiva A, Price D, Dahut W, Figg W, Prokunina-Olsson L. Abstract LB-350: Tissue and serum miRNA profiling for detection of bladder, breast and prostate cancer Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-350 |
0.36 |
|
| 2011 |
Sissung TM, Kirkland CT, Reece K, Arnold JT, Figg WD. Abstract 4535: Thalidomide inhibits the TGFβ-mediated synthesis of testosterone from DHEA in prostate cancer Cancer Research. 71: 4535-4535. DOI: 10.1158/1538-7445.Am2011-4535 |
0.41 |
|
| 2011 |
Reece KM, Pisle ST, Richardson ED, Cook KM, Price DK, Figg WD. Abstract 3095: The molecular, cellular, and physiological consequences of disrupting the HIF-1α interaction Cancer Research. 71: 3095-3095. DOI: 10.1158/1538-7445.Am2011-3095 |
0.336 |
|
| 2011 |
Pressler HM, Pisle S, Sissung TM, Cropp CD, Price DK, Figg WD. Abstract B28: Organic anion transporting polypeptide 1B3 as a novel biomarker for hypoxia in prostate cancer. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-B28 |
0.397 |
|
| 2010 |
English BC, Baum CE, Adelberg DE, Sissung TM, Kluetz PG, Dahut WL, Price DK, Figg WD. A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer. Therapeutics and Clinical Risk Management. 6: 579-83. PMID 21151627 DOI: 10.2147/Tcrm.S14303 |
0.374 |
|
| 2010 |
Goodman PJ, Tangen CM, Kristal AR, Thompson IM, Lucia MS, Platz EA, Figg WD, Hoque A, Hsing A, Neuhouser ML, Parnes HL, Reichardt JK, Santella RM, Till C, Lippman SM. Transition of a clinical trial into translational research: the prostate cancer prevention trial experience. Cancer Prevention Research (Philadelphia, Pa.). 3: 1523-33. PMID 21149329 DOI: 10.1158/1940-6207.Capr-09-0256 |
0.393 |
|
| 2010 |
Figg WD, Figg WD. Cabazitaxel: filling one of the gaps in the treatment of prostate cancer. Cancer Biology & Therapy. 10: 1233-4. PMID 21107022 DOI: 10.4161/CBT.10.12.14085 |
0.326 |
|
| 2010 |
Troutman SM, Price DK, Figg WD. Prostate cancer genomic signature offers prognostic value. Cancer Biology & Therapy. 10: 1079-1080. PMID 21088497 DOI: 10.4161/Cbt.10.11.14086 |
0.403 |
|
| 2010 |
Price DK, Chau CH, Till C, Goodman PJ, Baum CE, Ockers SB, English BC, Minasian L, Parnes HL, Hsing AW, Reichardt JK, Hoque A, Tangen CM, Kristal AR, Thompson IM, ... Figg WD, et al. Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial. The Journal of Urology. 184: 2297-302. PMID 20952028 DOI: 10.1016/J.Juro.2010.08.005 |
0.383 |
|
| 2010 |
Pastina I, Giovannetti E, Chioni A, Sissung TM, Crea F, Orlandini C, Price DK, Cianci C, Figg WD, Ricci S, Danesi R. Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients. Bmc Cancer. 10: 511. PMID 20875115 DOI: 10.1186/1471-2407-10-511 |
0.397 |
|
| 2010 |
Sharifi N, Qi J, Bane S, Sharma S, Li R, Robey R, Figg WD, Farrar WL, Kingston DG. Survivin is not induced by novel taxanes. Molecular Pharmaceutics. 7: 2216-23. PMID 20863081 DOI: 10.1021/Mp100211K |
0.332 |
|
| 2010 |
Pressler HM, Figg WD. Androgen synthesis and steroid transporters in prostate cancer: rethinking the transition to CRPC. Cancer Biology & Therapy. 9: 1043-5. PMID 20818170 DOI: 10.4161/Cbt.9.12.12265 |
0.378 |
|
| 2010 |
Reece KM, Figg WD. A novel regulator (USP10) of p53: Implications for tumor suppression and therapeutic targeting. Cancer Biology & Therapy. 9: 583-4. PMID 20720457 DOI: 10.4161/Cbt.9.8.11690 |
0.308 |
|
| 2010 |
Figg WD, Smith EK, Price DK, English BC, Thurman PW, Steinberg SM, Emanuel E. Disclosing a diagnosis of cancer: where and how does it occur? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 3630-5. PMID 20606078 DOI: 10.1200/Jco.2009.24.6389 |
0.337 |
|
| 2010 |
Kirkland CT, Price DK, Figg WD. Genetic variant associated with aggressive not indolent prostate cancer. Cancer Biology & Therapy. 9: 957-8. PMID 20581469 DOI: 10.4161/Cbt.9.12.12137 |
0.392 |
|
| 2010 |
Sun H, Pisle S, Gardner ER, Figg WD. Bioluminescent imaging study: FAK inhibitor, PF-562,271, preclinical study in PC3M-luc-C6 local implant and metastasis xenograft models. Cancer Biology & Therapy. 10: 38-43. PMID 20495381 DOI: 10.4161/Cbt.10.1.11993 |
0.357 |
|
| 2010 |
Gao R, Price DK, Dahut WL, Reed E, Figg WD. Genetic polymorphisms in XRCC1 associated with radiation therapy in prostate cancer Cancer Biology & Therapy. 10: 13-18. PMID 20495366 DOI: 10.4161/Cbt.10.1.12172 |
0.373 |
|
| 2010 |
Figg WD, Woo S, Zhu W, Chen X, Ajiboye AS, Steinberg SM, Price DK, Wright JJ, Parnes HL, Arlen PM, Gulley JL, Dahut WL. A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer. The Journal of Urology. 183: 2219-26. PMID 20399458 DOI: 10.1016/J.Juro.2010.02.020 |
0.407 |
|
| 2010 |
Ning YM, Gulley JL, Arlen PM, Woo S, Steinberg SM, Wright JJ, Parnes HL, Trepel JB, Lee MJ, Kim YS, Sun H, Madan RA, Latham L, Jones E, Chen CC, ... Figg WD, et al. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 2070-6. PMID 20308663 DOI: 10.1200/Jco.2009.25.4524 |
0.432 |
|
| 2010 |
Baum CE, Price DK, Figg WD. Sarcosine as a potential prostate cancer biomarker and therapeutic target. Cancer Biology & Therapy. 9: 341-2. PMID 20150759 DOI: 10.4161/Cbt.9.5.11310 |
0.397 |
|
| 2010 |
Kluetz PG, Figg WD, Dahut WL. Angiogenesis Inhibitors in the treatment of Prostate Cancer Expert Opinion On Pharmacotherapy. 11: 233-247. PMID 20088745 DOI: 10.1517/14656560903451716 |
0.418 |
|
| 2010 |
Sharma H, Sissung TM, Pressler H, Figg WD. Stromal-epithelial interactions are responsible for prostate tumor progression through an androgen-related mechanism. Cancer Biology & Therapy. 9: 163-5. PMID 20087060 DOI: 10.4161/Cbt.9.3.11143 |
0.368 |
|
| 2010 |
Ajiboye S, Sissung TM, Sharifi N, Figg WD. More than an accessory: implications of type III transforming growth factor-beta receptor loss in prostate cancer. Bju International. 105: 913-6. PMID 20067462 DOI: 10.1111/J.1464-410X.2009.08999.X |
0.346 |
|
| 2010 |
Baum CE, Ockers SB, English BC, Price DK, Sartor O, Figg WD. Androgen receptor sequence and variations in several common prostate cancer cell lines. Cancer Biology & Therapy. 9: 383-8. PMID 20061791 DOI: 10.4161/Cbt.9.5.10891 |
0.333 |
|
| 2010 |
Zhu W, Zhu DS, Madan RA, Gulley JL, Figg WD, Dahut WL. Treatment of castration-resistant prostate cancer: updates on therapeutics targeting the androgen receptor signaling pathway. American Journal of Therapeutics. 17: 176-81. PMID 20019584 DOI: 10.1097/Mjt.0B013E3181C6C0B2 |
0.368 |
|
| 2010 |
Kummar S, Gutierrez ME, Gardner ER, Chen X, Figg WD, Zajac-Kaye M, Chen M, Steinberg SM, Muir CA, Yancey MA, Horneffer YR, Juwara L, Melillo G, Ivy SP, Merino M, et al. Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. European Journal of Cancer (Oxford, England : 1990). 46: 340-7. PMID 19945858 DOI: 10.1016/J.Ejca.2009.10.026 |
0.335 |
|
| 2010 |
Kristal AR, Price DK, Till C, Schenk JM, Neuhouser ML, Ockers S, Lin DW, Thompson IM, Figg WD. Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. The Prostate. 70: 584-90. PMID 19938041 DOI: 10.1002/Pros.21092 |
0.352 |
|
| 2010 |
Kummar S, Gutierrez ME, Gardner ER, Figg WD, Melillo G, Dancey J, Sausville EA, Conley BA, Murgo AJ, Doroshow JH. A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas. Cancer Chemotherapy and Pharmacology. 65: 383-9. PMID 19894051 DOI: 10.1007/S00280-009-1154-Y |
0.32 |
|
| 2010 |
Ning YM, Figg WD, Dahut WL. Reversal of docetaxel resistance with bevacizumab and thalidomide. Clinical Genitourinary Cancer. 7: E37-8. PMID 19692321 DOI: 10.3816/Cgc.2009.N.020 |
0.332 |
|
| 2010 |
Scripture CD, Figg WD, Sparreboom A. Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives. Current Neuropharmacology. 4: 165-72. PMID 18615126 DOI: 10.2174/157015906776359568 |
0.314 |
|
| 2010 |
Kelly RJ, Robey R, Draper D, Chen C, Venkatesan AM, Figg WD, Gardner E, Piekarz R, Balis F, Fojo T, Bates SE. Abstract 3527: A pharmacodynamic study of docetaxel in combination with the p-glycoprotein antagonist, tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer Cancer Research. 70: 3527-3527. DOI: 10.1158/1538-7445.Am10-3527 |
0.398 |
|
| 2010 |
Pressler H, Sissung T, Price D, Figg W. 642 Organic anion transporting polypeptides contribute to prostate cancer progression European Journal of Cancer Supplements. 8: 201. DOI: 10.1016/S1359-6349(10)72349-1 |
0.359 |
|
| 2009 |
Karakunnel JJ, Gulley JL, Arlen P, Mulquin M, Wright J, Turkbey IB, Choyke P, Figg WD, Dahut W. Cediranib (AZD2171) in docetaxel-resistant, castration-resistant prostate cancer (CRPC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5141. PMID 27964432 DOI: 10.1200/Jco.2009.27.15_Suppl.5141 |
0.407 |
|
| 2009 |
Dennis PA, Blumenthal G, Ballas M, Gardner E, Kawabata S, LoPiccolo J, Helsabeck C, Root H, Figg WD, Bernstein W. A phase I study of nelfinavir, an FDA approved HIV protease inhibitor, in adults with refractory solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2583. PMID 27961900 DOI: 10.1200/Jco.2009.27.15_Suppl.2583 |
0.312 |
|
| 2009 |
Deeken JF, Cormier T, Price DK, Sissung TM, Steinberg SM, Tran K, Liewehr DJ, Dahut WL, Miao X, Figg WD. A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform. The Pharmacogenomics Journal. 10: 191-9. PMID 20038957 DOI: 10.1038/Tpj.2009.57 |
0.353 |
|
| 2009 |
Platz EA, Till C, Goodman PJ, Parnes HL, Figg WD, Albanes D, Neuhouser ML, Klein EA, Thompson IM, Kristal AR. Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 18: 2807-13. PMID 19887582 DOI: 10.1158/1055-9965.Epi-09-0472 |
0.384 |
|
| 2009 |
Jonsson JG, Sissung TM, Figg WD. A genomic strategy for predicting androgen receptor activity in prostate tumors. Cancer Biology & Therapy. 8: 2002-3. PMID 19838047 DOI: 10.4161/Cbt.8.21.10180 |
0.372 |
|
| 2009 |
Pisle ST, Figg WD. Antiandrogens in the 21st century. Cancer Biology & Therapy. 8: 1611. PMID 19823041 DOI: 10.4161/Cbt.8.17.9617 |
0.41 |
|
| 2009 |
Jain L, Vargo CA, Danesi R, Sissung TM, Price DK, Venzon D, Venitz J, Figg WD. The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Molecular Cancer Therapeutics. 8: 2496-508. PMID 19755511 DOI: 10.1158/1535-7163.Mct-09-0302 |
0.353 |
|
| 2009 |
Azad N, Perroy A, Gardner E, Imamura CK, Graves C, Sarosy GA, Minasian L, Kotz H, Raggio M, Figg WD, Kohn EC. A phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors. Cancer Biology & Therapy. 8: 1800-1805. PMID 19738417 DOI: 10.4161/Cbt.8.19.9593 |
0.363 |
|
| 2009 |
Sissung TM, Thordardottir S, Gardner ER, Figg WD. Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer. Anti-Cancer Agents in Medicinal Chemistry. 9: 1058-69. PMID 19719457 DOI: 10.2174/187152009789735017 |
0.408 |
|
| 2009 |
Russo AL, Jedlicka K, Wernick M, McNally D, Kirk M, Sproull M, Smith S, Shankavaram U, Kaushal A, Figg WD, Dahut W, Citrin D, Bottaro DP, Albert PS, Tofilon PJ, et al. Urine analysis and protein networking identify met as a marker of metastatic prostate cancer Clinical Cancer Research. 15: 4292-4298. PMID 19549766 DOI: 10.1158/1078-0432.Ccr-09-0599 |
0.398 |
|
| 2009 |
Mucci LA, Stark JR, Figg WD, Schumacher F, Li H, Abe M, Hennessy K, Stampfer MJ, Gaziano JM, Ma J, Kantoff PW. Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study. International Journal of Cancer. Journal International Du Cancer. 125: 1143-6. PMID 19431146 DOI: 10.1002/Ijc.24423 |
0.39 |
|
| 2009 |
Wolfe ME, Yagoda D, Thurman PW, Luna JM, Figg WD. NCI designated cancer center funding not influenced by organizational structure. Cancer Biology & Therapy. 8: 869-73. PMID 19270497 DOI: 10.4161/Cbt.8.10.8120 |
0.317 |
|
| 2009 |
Aragon-Ching JB, Ning YM, Chen CC, Latham L, Guadagnini JP, Gulley JL, Arlen PM, Wright JJ, Parnes H, Figg WD, Dahut WL. Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Investigation. 27: 221-6. PMID 19235596 DOI: 10.1080/07357900802208608 |
0.432 |
|
| 2009 |
Figg WD, Hussain MH, Gulley JL, Arlen PM, Aragon-Ching JB, Petrylak DP, Higano CS, Steinberg SM, Chatta GS, Parnes H, Wright JJ, Sartor O, Dahut WL. A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. The Journal of Urology. 181: 1104-1113. PMID 19167733 DOI: 10.1016/J.Juro.2008.11.026 |
0.398 |
|
| 2009 |
Scripture CD, Figg WD, Sparreboom A. The role of drug-metabolising enzymes in clinical responses to chemotherapy. Expert Opinion On Drug Metabolism & Toxicology. 2: 17-25. PMID 16863465 DOI: 10.1517/17425255.2.1.17 |
0.332 |
|
| 2009 |
Chau CH, Figg WD. New tricks from an old drug: A role for quinacrine in anti-cancer therapy? Cell Cycle. 8: 4023-4028. DOI: 10.4161/Cc.8.24.10473 |
0.316 |
|
| 2009 |
Giaccone G, Rajan A, Crandon S, Gutierrez M, Kummar S, Jain L, Figg WD, Houk BE, Shnaidman M, Skillings J. Abstract A110: A phase 1 study of PF‐04929113 (SNX5422), an orally bioavailable heat shock protein 90 (Hsp90) inhibitor administered twice weekly in patients with refractory solid tumor malignancies and lymphoma Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-A110 |
0.384 |
|
| 2008 |
Karakunnel JJ, Gulley JL, Arlen PM, Mulquin M, Wright JJ, Turkbey IB, Choyke P, Ahlers CM, Figg WD, Dahut WL. Phase II trial of cediranib (AZD2171) in docetaxel-resistant, castrate-resistant prostate cancer (CRPC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5136. PMID 27948217 DOI: 10.1200/jco.2008.26.15_suppl.5136 |
0.323 |
|
| 2008 |
Sung SY, Hsieh CL, Law A, Zhau HE, Pathak S, Multani AS, Lim S, Coleman IM, Wu LC, Figg WD, Dahut WL, Nelson P, Lee JK, Amin MB, Lyles R, et al. Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. Cancer Research. 68: 9996-10003. PMID 19047182 DOI: 10.1158/0008-5472.Can-08-2492 |
0.378 |
|
| 2008 |
Miles RJ, Price DK, Figg WD. Temporal-mediated FGFR1 independence: implications for targeting candidate molecules in prostate cancer. Cancer Biology & Therapy. 7: 1180-1. PMID 18719360 DOI: 10.4161/Cbt.7.8.6658 |
0.387 |
|
| 2008 |
Gulley JL, Aragon-Ching JB, Steinberg SM, Hussain MH, Sartor O, Higano CS, Petrylak DP, Chatta GS, Arlen PM, Figg WD, Dahut WL. Kinetics of Serum Androgen Normalization and Factors Associated With Testosterone Reserve After Limited Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer The Journal of Urology. 180: 1432-1437. PMID 18710748 DOI: 10.1016/J.Juro.2008.06.017 |
0.366 |
|
| 2008 |
Sharifi N, Dahut WL, Figg WD. The genetics of castration-resistant prostate cancer: what can the germline tell us? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 4691-3. PMID 18676736 DOI: 10.1158/1078-0432.Ccr-08-0453 |
0.416 |
|
| 2008 |
Sissung TM, Baum CE, Deeken J, Price DK, Aragon-Ching J, Steinberg SM, Dahut W, Sparreboom A, Figg WD. ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 4543-9. PMID 18628469 DOI: 10.1158/1078-0432.Ccr-07-4230 |
0.422 |
|
| 2008 |
Gardner ER, Dahut WL, Scripture CD, Jones J, Aragon-Ching JB, Desai N, Hawkins MJ, Sparreboom A, Figg WD. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 4200-5. PMID 18594000 DOI: 10.1158/1078-0432.Ccr-07-4592 |
0.348 |
|
| 2008 |
Sharifi N, Hamada A, Sissung T, Danesi R, Venzon D, Baum C, Gulley JL, Price DK, Dahut WL, Figg WD. A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. Bju International. 102: 617-21. PMID 18537956 DOI: 10.1111/J.1464-410X.2008.07629.X |
0.379 |
|
| 2008 |
Hamada A, Sissung T, Price DK, Danesi R, Chau CH, Sharifi N, Venzon D, Maeda K, Nagao K, Sparreboom A, Mitsuya H, Dahut WL, Figg WD. Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 3312-8. PMID 18519758 DOI: 10.1158/1078-0432.Ccr-07-4118 |
0.403 |
|
| 2008 |
Chu Z, Chen JS, Liau CT, Wang HM, Lin YC, Yang MH, Chen PM, Gardner ER, Figg WD, Sparreboom A. Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients. Anti-Cancer Drugs. 19: 275-81. PMID 18510173 DOI: 10.1097/Cad.0B013E3282F3Fd2E |
0.321 |
|
| 2008 |
Smith NF, Baker SD, Gonzalez FJ, Harris JW, Figg WD, Sparreboom A. Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100. British Journal of Cancer. 98: 1630-2. PMID 18475295 DOI: 10.1038/Sj.Bjc.6604353 |
0.308 |
|
| 2008 |
Arlen PM, Bianco F, Dahut WL, D'Amico A, Figg WD, Freedland SJ, Gulley JL, Kantoff PW, Kattan MW, Lee A, Regan MM, Sartor O. Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. The Journal of Urology. 179: 2181-5; discussion 2. PMID 18423743 DOI: 10.1016/J.Juro.2008.01.099 |
0.345 |
|
| 2008 |
Chen X, Gardner ER, Price DK, Figg WD. Development and validation of an LC-MS assay for finasteride and its application to prostate cancer prevention trial sample analysis. Journal of Chromatographic Science. 46: 356-61. PMID 18402729 DOI: 10.1093/Chromsci/46.4.356 |
0.357 |
|
| 2008 |
Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 1148-59. PMID 18309951 DOI: 10.1200/Jco.2007.12.4487 |
0.408 |
|
| 2008 |
Di Lorenzo G, Figg WD, Fossa SD, Mirone V, Autorino R, Longo N, Imbimbo C, Perdonà S, Giordano A, Giuliano M, Labianca R, De Placido S. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. European Urology. 54: 1089-94. PMID 18276061 DOI: 10.1016/J.Eururo.2008.01.082 |
0.418 |
|
| 2008 |
Sissung TM, Danesi R, Price DK, Steinberg SM, de Wit R, Zahid M, Gaikwad N, Cavalieri E, Dahut WL, Sackett DL, Figg WD, Sparreboom A. Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Molecular Cancer Therapeutics. 7: 19-26. PMID 18187806 DOI: 10.1158/1535-7163.Mct-07-0557 |
0.407 |
|
| 2008 |
Dahut WL, Scripture C, Posadas E, Jain L, Gulley JL, Arlen PM, Wright JJ, Yu Y, Cao L, Steinberg SM, Aragon-Ching JB, Venitz J, Jones E, Chen CC, Figg WD. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 209-14. PMID 18172272 DOI: 10.1158/1078-0432.Ccr-07-1355 |
0.407 |
|
| 2008 |
Schrump DS, Fischette MR, Nguyen DM, Zhao M, Li X, Kunst TF, Hancox A, Hong JA, Chen GA, Kruchin E, Wright JJ, Rosing DR, Sparreboom A, Figg WD, Steinberg SM. Clinical and molecular responses in lung cancer patients receiving Romidepsin. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 188-98. PMID 18172270 DOI: 10.1158/1078-0432.Ccr-07-0135 |
0.337 |
|
| 2008 |
Fine HA, Kim L, Albert PS, Duic JP, Ma H, Zhang W, Tohnya T, Figg WD, Royce C. A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 7101-6. PMID 18056189 DOI: 10.1158/1078-0432.Ccr-07-1546 |
0.324 |
|
| 2008 |
Sharifi N, Dahut WL, Figg WD. Secondary hormonal therapy for prostate cancer: what lies on the horizon? Bju International. 101: 271-4. PMID 17922868 DOI: 10.1111/J.1464-410X.2007.07236.X |
0.394 |
|
| 2008 |
Lal S, Wong ZW, Jada SR, Xiang X, Chen Shu X, Ang PC, Figg WD, Lee EJ, Chowbay B. Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. Pharmacogenomics. 8: 567-75. PMID 17559346 DOI: 10.2217/14622416.8.6.567 |
0.314 |
|
| 2007 |
Li H, Raia V, Bertolini F, Price DK, Figg WD. Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model. Bju International. 101: 884-8. PMID 18070197 DOI: 10.1111/J.1464-410X.2007.07342.X |
0.313 |
|
| 2007 |
Aragon-Ching JB, Li H, Gardner ER, Figg WD. Thalidomide analogues as anticancer drugs. Recent Patents On Anti-Cancer Drug Discovery. 2: 167-74. PMID 17975653 DOI: 10.2174/157489207780832478 |
0.347 |
|
| 2007 |
Sharifi N, Figg WD. Androgen receptor modulation: lessons learned from beyond the prostate. Cancer Biology & Therapy. 6: 1358-9. PMID 17881894 DOI: 10.4161/Cbt.6.9.4825 |
0.374 |
|
| 2007 |
Kummar S, Gutierrez M, Gardner ER, Donovan E, Hwang K, Chung EJ, Lee MJ, Maynard K, Kalnitskiy M, Chen A, Melillo G, Ryan QC, Conley B, Figg WD, Trepel JB, et al. Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 5411-7. PMID 17875771 DOI: 10.1158/1078-0432.Ccr-07-0791 |
0.343 |
|
| 2007 |
Aragon-Ching JB, Gillespie J, Price DK, Chuaqui R, Rodriguez-Canales J, Steinberg SM, Dahut WL, Figg WD. Lack of prognostic significance of prostate biopsies in metastatic androgen independent prostate cancer Bjui. 100: 1245-1248. PMID 17850370 DOI: 10.1111/J.1464-410X.2007.07173.X |
0.375 |
|
| 2007 |
Hamada A, Danesi R, Price DK, Sissung T, Chau C, Venzon D, Sparreboom A, Dahut WL, Figg WD. Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer. Urology. 70: 217-220. PMID 17826473 DOI: 10.1016/J.Urology.2007.06.1097 |
0.326 |
|
| 2007 |
Di Lorenzo G, Autorino R, Figg WD, De Placido S. Hormone-refractory prostate cancer: where are we going? Drugs. 67: 1109-24. PMID 17521214 DOI: 10.2165/00003495-200767080-00002 |
0.409 |
|
| 2007 |
Al-Chalabi T, Figg WD. Benefits of the combination of thalidomide plus cyclophosphamide in hormone refractory prostate cancer patients. Cancer Biology & Therapy. 6: 318-319. PMID 17471018 DOI: 10.4161/Cbt.6.3.4235 |
0.413 |
|
| 2007 |
Figg WD, Li H, Sissung T, Retter A, Wu S, Gulley JL, Arlen P, Wright JJ, Parnes H, Fedenko K, Latham L, Steinberg SM, Jones E, Chen C, Dahut W. Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. Bju International. 99: 1047-55. PMID 17437439 DOI: 10.1111/J.1464-410X.2007.06763.X |
0.403 |
|
| 2007 |
Li H, Price DK, Figg WD. ADH1, an N-cadherin inhibitor, evaluated in preclinical models of angiogenesis and androgen-independent prostate cancer. Anti-Cancer Drugs. 18: 563-8. PMID 17414625 DOI: 10.1097/Cad.0B013E328020043E |
0.392 |
|
| 2007 |
Di Lorenzo G, Autorino R, Perdonà S, De Laurentiis M, D'Armiento M, Cancello G, Mirone V, Imbimbo C, Longo N, Altieri V, Tortora G, Figg WD, De Placido S. Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. European Urology. 52: 1020-7. PMID 17360103 DOI: 10.1016/J.Eururo.2007.02.060 |
0.391 |
|
| 2007 |
Lakhani NJ, Sparreboom A, Xu X, Veenstra TD, Venitz J, Dahut WL, Figg WD. Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent, 2-methoxyestradiol. Journal of Pharmaceutical Sciences. 96: 1821-31. PMID 17252610 DOI: 10.1002/Jps.20837 |
0.612 |
|
| 2007 |
Gojo I, Jiemjit A, Trepel JB, Sparreboom A, Figg WD, Rollins S, Tidwell ML, Greer J, Chung EJ, Lee MJ, Gore SD, Sausville EA, Zwiebel J, Karp JE. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood. 109: 2781-90. PMID 17179232 DOI: 10.1182/Blood-2006-05-021873 |
0.309 |
|
| 2007 |
Deeken JF, Figg WD, Bates SE, Sparreboom A. Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics. Anti-Cancer Drugs. 18: 111-26. PMID 17159598 DOI: 10.1097/Cad.0B013E3280109411 |
0.351 |
|
| 2007 |
Wu SL, Jones E, Gulley JL, Arlen PM, Chen CC, Figg WD, Dahut WL. Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone. Bjui. 99: 525-528. PMID 17155971 DOI: 10.1111/J.1464-410X.2006.06654.X |
0.32 |
|
| 2007 |
Sartor O, Alchalabi T, Figg WD. Assessing progress against prostate cancer. Clinical Genitourinary Cancer. 5: 102-3. PMID 17026796 DOI: 10.3816/Cgc.2006.N.025 |
0.404 |
|
| 2007 |
Parnes HL, Figg WD. Chemoprevention in prostate cancer. Pharmacotherapy. 26: 1533; author reply 1. PMID 16999665 DOI: 10.1592/Phco.26.10.1533 |
0.383 |
|
| 2007 |
Cox MC, Low J, Lee J, Walshe J, Denduluri N, Berman A, Permenter MG, Petros WP, Price DK, Figg WD, Sparreboom A, Swain SM. Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4636-40. PMID 16899612 DOI: 10.1158/1078-0432.Ccr-06-0388 |
0.336 |
|
| 2007 |
Hamada A, Price DK, Sissung T, Venzon D, Duhut WL, Figg WD. Pharmacogenetics of organic anion transporting peptides (OATP): An association of a SLCO1B3 polymorphism with the overall survival in white Caucasian patients with androgen independent prostate cancer Journal of Clinical Oncology. 25: 5118-5118. DOI: 10.1200/Jco.2007.25.18_Suppl.5118 |
0.405 |
|
| 2007 |
Schrump D, Fischette M, Nguyen D, Zhao M, Li X, Kunst T, Hancox A, Hong J, Chen G, Kruchin E, Wright J, Rosing D, Sparreboom A, Figg W, Steinberg S. Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin Clinical Lung Cancer. 8: 453. DOI: 10.1016/S1525-7304(11)70818-X |
0.389 |
|
| 2006 |
Schrump DS, Fischette MR, Nguyen DM, Zhao M, Li X, Kunst TF, Hancox A, Hong JA, Chen GA, Pishchik V, Figg WD, Murgo AJ, Steinberg SM. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 5777-85. PMID 17020984 DOI: 10.1158/1078-0432.Ccr-06-0669 |
0.393 |
|
| 2006 |
Beverage JN, Figg WD. The quantification of PSA mRNA copies in pathologically normal pelvic lymph nodes is a viable prognostic indicator. Cancer Biology & Therapy. 5: 1094-1095. PMID 17012834 DOI: 10.4161/Cbt.5.9.3287 |
0.342 |
|
| 2006 |
Jain L, Venitz J, Figg WD. Randomized discontinuation trial of sorafenib (BAY 43-9006). Cancer Biology & Therapy. 5: 1270-2. PMID 16969070 DOI: 10.4161/Cbt.5.10.3290 |
0.306 |
|
| 2006 |
Sissung TM, Mross K, Steinberg SM, Behringer D, Figg WD, Sparreboom A, Mielke S. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. European Journal of Cancer (Oxford, England : 1990). 42: 2893-6. PMID 16950614 DOI: 10.1016/J.Ejca.2006.06.017 |
0.305 |
|
| 2006 |
Lakhani N, Sparreboom A, Venitz J, Dahut WL, Figg WD. Plasma protein binding of the investigational anticancer agent 2-methoxyestradiol. Anti-Cancer Drugs. 17: 977-83. PMID 16940808 DOI: 10.1097/01.Cad.0000224447.08706.92 |
0.644 |
|
| 2006 |
Ng SS, Sparreboom A, Shaked Y, Lee C, Man S, Desai N, Soon-Shiong P, Figg WD, Kerbel RS. Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4331-8. PMID 16857808 DOI: 10.1158/1078-0432.Ccr-05-2762 |
0.338 |
|
| 2006 |
Scripture CD, Figg WD. Drug interactions in cancer therapy. Nature Reviews. Cancer. 6: 546-58. PMID 16794637 DOI: 10.1038/Nrc1887 |
0.302 |
|
| 2006 |
Warfel NA, Lepper ER, Zhang C, Figg WD, Dennis PA. Importance of the stress kinase p38alpha in mediating the direct cytotoxic effects of the thalidomide analogue, CPS49, in cancer cells and endothelial cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 3502-9. PMID 16740776 DOI: 10.1158/1078-0432.Ccr-05-1837 |
0.342 |
|
| 2006 |
Cox MC, Dahut WL, Figg WD. The use of thalidomide in androgen-independent prostate cancer. Urologic Oncology. 24: 246-9. PMID 16678058 DOI: 10.1016/J.Urolonc.2005.11.020 |
0.403 |
|
| 2006 |
Ahlers CM, Figg WD. ETS-TMPRSS2 fusion gene products in prostate cancer. Cancer Biology & Therapy. 5: 254-255. PMID 16575200 DOI: 10.4161/Cbt.5.3.2603 |
0.359 |
|
| 2006 |
Sissung TM, Price DK, Sparreboom A, Figg WD. Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention. Molecular Cancer Research : McR. 4: 135-50. PMID 16547151 DOI: 10.1158/1541-7786.Mcr-05-0101 |
0.381 |
|
| 2006 |
Singh AS, Chau CH, Price DK, Figg WD. Mechanisms of disease: Polymorphisms of androgen regulatory genes in the development of prostate cancer. Nature Clinical Practice. Urology. 2: 101-7. PMID 16474655 DOI: 10.1038/Ncpuro0091 |
0.376 |
|
| 2006 |
Figg WD. The 2005 Leon I. Goldberg Young Investigator Award Lecture: Development of thalidomide as an angiogenesis inhibitor for the treatment of androgen-independent prostate cancer. Clinical Pharmacology and Therapeutics. 79: 1-8. PMID 16413236 DOI: 10.1016/J.Clpt.2005.09.006 |
0.397 |
|
| 2006 |
Travis LB, Rabkin CS, Brown LM, Allan JM, Alter BP, Ambrosone CB, Begg CB, Caporaso N, Chanock S, DeMichele A, Figg WD, Gospodarowicz MK, Hall EJ, Hisada M, Inskip P, et al. Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations. Journal of the National Cancer Institute. 98: 15-25. PMID 16391368 DOI: 10.1093/Jnci/Djj001 |
0.348 |
|
| 2006 |
Dahut WL, Lakhani NJ, Gulley JL, Arlen PM, Kohn EC, Kotz H, McNally D, Parr A, Nguyen D, Yang SX, Steinberg SM, Venitz J, Sparreboom A, Figg WD. Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biology & Therapy. 5: 22-7. PMID 16357512 DOI: 10.4161/Cbt.5.1.2349 |
0.666 |
|
| 2006 |
Rozhansky F, Chen M, Cox MC, Dahut W, Figg WD, D'Amico AV. Prostate‐specific antigen velocity and survival for patients with hormone‐refractory metastatic prostate carcinoma Cancer. 106: 63-67. PMID 16333854 DOI: 10.1002/Cncr.21576 |
0.365 |
|
| 2006 |
Cox MC, Scripture CD, Figg WD. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain? Expert Review of Anticancer Therapy. 5: 605-11. PMID 16111462 DOI: 10.1586/14737140.5.4.605 |
0.344 |
|
| 2006 |
Tohny T, Venitz J, Sparreboom A, Figg W. Lenalidomide: Cancer Therapy via Antiangiogenesis and Immunomodulation Current Cancer Therapy Reviews. 2: 223-229. DOI: 10.2174/157339406777934690 |
0.322 |
|
| 2006 |
Dahut WL, Scripture CD, Posadas EM, Wu S, Arlen PM, Gulley JL, Wright J, Chen CC, Jones E, Figg WD. Bony metastatic disease responses to sorafenib (BAY 43–9006) independent of PSA in patients with metastatic androgen independent prostate cancer Journal of Clinical Oncology. 24: 4506-4506. DOI: 10.1200/JCO.2006.24.18_SUPPL.4506 |
0.313 |
|
| 2006 |
Piekarz RL, Frye R, Turner M, Wright J, Allen S, Kirschbaum MH, Zain J, Prince M, Hutchins L, Showe LC, Figg WD, Fojo T, Bates SE. Phase II Trial of Romidepsin, FK228, in Cutaneous and Peripheral T-Cell Lymphoma: Clinical Activity and Molecular Markers. Blood. 108: 2469-2469. DOI: 10.1182/Blood.V108.11.2469.2469 |
0.358 |
|
| 2006 |
Scripture CD, Figg WD. Erratum: Drug interactions in cancer therapy Nature Reviews Cancer. 6: 741-741. DOI: 10.1038/Nrc1975 |
0.317 |
|
| 2006 |
Scripture CD, Figg WD. Epidemiology of drug interactions in cancer patients Nature Reviews Cancer. 6: 824-824. DOI: 10.1038/Nrc1887-C2 |
0.334 |
|
| 2006 |
Wu S, Retter A, Arlen PM, Gulley JL, Latham LL, Steinberg SM, Parnes H, Wright JJ, Chen C, Jones E, Figg WD, Dahut WL. 978: A Phase II Trial of Docetaxel, Thalidomide and Estramustine in Metastatic Androgen-Independent Prostate Cancer The Journal of Urology. 175: 315-316. DOI: 10.1016/S0022-5347(18)33203-8 |
0.395 |
|
| 2006 |
LI J, RUDEK M, VENITZ J, REED E, FIGG W, KARLSSON M. PI-51Population pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer Clinical Pharmacology & Therapeutics. 79: P20-P20. DOI: 10.1016/J.Clpt.2005.12.072 |
0.561 |
|
| 2005 |
Longoria RL, Cox MC, Figg WD. Antiangiogenesis: a possible treatment option for prostate cancer? Clinical Genitourinary Cancer. 4: 197-202. PMID 16425989 DOI: 10.3816/Cgc.2005.N.033 |
0.417 |
|
| 2005 |
Lepper ER, Baker SD, Permenter M, Ries N, van Schaik RH, Schenk PW, Price DK, Ahn D, Smith NF, Cusatis G, Ingersoll RG, Bates SE, Mathijssen RH, Verweij J, Figg WD, et al. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 7398-404. PMID 16243813 DOI: 10.1158/1078-0432.Ccr-05-0520 |
0.333 |
|
| 2005 |
Gulley J, Figg WD, Dahut WL. Treatment options for androgen-independent prostate cancer. Clinical Advances in Hematology & Oncology : H&O. 1: 49-57. PMID 16227960 |
0.314 |
|
| 2005 |
Sharifi N, Dahut WL, Steinberg SM, Figg WD, Tarassoff C, Arlen P, Gulley JL. A retrospective study of the time to clinical endpoints for advanced prostate cancer. Bju International. 96: 985-9. PMID 16225513 DOI: 10.1111/J.1464-410X.2005.05798.X |
0.419 |
|
| 2005 |
Chau CH, Permenter MG, Steinberg SM, Retter AS, Dahut WL, Price DK, Figg WD. Polymorphism in the hypoxia-inducible factor 1α gene may confer susceptibility to androgen-independent prostate cancer Cancer Biology & Therapy. 4: 1222-1225. PMID 16205110 DOI: 10.4161/Cbt.4.11.2091 |
0.366 |
|
| 2005 |
Best CJ, Gillespie JW, Yi Y, Chandramouli GV, Perlmutter MA, Gathright Y, Erickson HS, Georgevich L, Tangrea MA, Duray PH, González S, Velasco A, Linehan WM, Matusik RJ, Price DK, ... Figg WD, et al. Molecular alterations in primary prostate cancer after androgen ablation therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 6823-34. PMID 16203770 DOI: 10.1158/1078-0432.Ccr-05-0585 |
0.393 |
|
| 2005 |
Scripture CD, Sparreboom A, Figg WD. Modulation of cytochrome P450 activity: implications for cancer therapy. The Lancet. Oncology. 6: 780-9. PMID 16198984 DOI: 10.1016/S1470-2045(05)70388-0 |
0.342 |
|
| 2005 |
D’Amico AV, Chen M, Cox MC, Dahut W, Figg WD. Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer. Urology. 66: 571-576. PMID 16140080 DOI: 10.1016/J.Urology.2005.03.083 |
0.39 |
|
| 2005 |
Posadas EM, Gulley J, Arlen PM, Trout A, Parnes HL, Wright J, Lee MJ, Chung EJ, Trepel JB, Sparreboom A, Chen C, Jones E, Steinberg SM, Daniels A, Figg WD, et al. A phase II study of perifosine in androgen independent prostate cancer. Cancer Biology & Therapy. 4: 1133-7. PMID 16138006 DOI: 10.4161/Cbt.4.10.2064 |
0.417 |
|
| 2005 |
Tkacz VL, Tohnya TM, Figg WD. Cyclooxygenase-2 and angiogenesis in prostate cancer. Cancer Biology & Therapy. 4: 813-814. PMID 16123581 DOI: 10.4161/Cbt.4.8.2089 |
0.403 |
|
| 2005 |
Singh AS, Figg WD. In vivo models of prostate cancer metastasis to bone. The Journal of Urology. 174: 820-6. PMID 16093963 DOI: 10.1097/01.Ju.0000169133.82167.Aa |
0.366 |
|
| 2005 |
Scripture CD, Szebeni J, Loos WJ, Figg WD, Sparreboom A. Comparative in vitro properties and clinical pharmacokinetics of paclitaxel following the administration of taxol® and paxene® Cancer Biology & Therapy. 4: 555-560. PMID 15917657 DOI: 10.4161/Cbt.4.5.1664 |
0.317 |
|
| 2005 |
Lepper ER, Nooter K, Verweij J, Acharya MR, Figg WD, Sparreboom A. Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics. 6: 115-38. PMID 15882131 DOI: 10.1517/14622416.6.2.115 |
0.308 |
|
| 2005 |
Cox MC, Permenter M, Figg WD. Angiogenesis and prostate cancer: important laboratory and clinical findings. Current Oncology Reports. 7: 215-9. PMID 15847713 DOI: 10.1007/S11912-005-0076-Z |
0.434 |
|
| 2005 |
Lakhani NJ, Lepper ER, Sparreboom A, Dahut WL, Venitz J, Figg WD. Determination of 2-methoxyestradiol in human plasma, using liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry : Rcm. 19: 1176-82. PMID 15818726 DOI: 10.1002/Rcm.1902 |
0.599 |
|
| 2005 |
Chau CH, Figg WD. Molecular and phenotypic heterogeneity of metastatic prostate cancer. Cancer Biology & Therapy. 4: 166-167. PMID 15738648 DOI: 10.4161/Cbt.4.2.1571 |
0.4 |
|
| 2005 |
Paoluzzi L, Singh AS, Price DK, Danesi R, Mathijssen RH, Verweij J, Figg WD, Sparreboom A. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. Journal of Clinical Pharmacology. 44: 854-60. PMID 15286088 DOI: 10.1200/Jco.2004.22.90140.2072 |
0.3 |
|
| 2005 |
Acharya MR, Baker SD, Verweij J, Figg WD, Sparreboom A. Determination of fraction unbound docetaxel using microequilibrium dialysis. Analytical Biochemistry. 331: 192-4. PMID 15246014 DOI: 10.1016/J.Ab.2004.03.045 |
0.352 |
|
| 2005 |
Cox MC, Figg WD. Book Review: Management of Prostate Cancer, 2nd Edition Annals of Pharmacotherapy. 39: 390-391. DOI: 10.1345/Aph.1E452 |
0.353 |
|
| 2005 |
D’Amico AV, Chen M, Cox MC, Dahut W, Figg WD. Intermediate end point for survival for patients with hormone refractory metastatic prostate cancer Journal of Clinical Oncology. 23: 4553-4553. DOI: 10.1200/Jco.2005.23.16_Suppl.4553 |
0.387 |
|
| 2005 |
Lakhani NJ, Sparreboom A, Venitz J, Dahut W, Figg WD. Single oral dose pharmacokinetics (PK) and safety of 2-methoxyestradiol (2ME2) in patients with solid tumors Journal of Clinical Oncology. 23: 2071-2071. DOI: 10.1200/Jco.2005.23.16_Suppl.2071 |
0.618 |
|
| 2005 |
Grant S, Karp JE, Koc ON, Cooper B, Luger S, Figg WD, Egorin M, Druker BJ, Jacobberger JW, Ramakrishnan V, Perkins EB, Colevas AD, Roberts JD. Phase I Study of Flavopiridol in Combination with Imatinib Mesylate (STI571, Gleevec) in Bcr/Abl+ Hematological Malignancies. Blood. 106: 1102-1102. DOI: 10.1182/Blood.V106.11.1102.1102 |
0.365 |
|
| 2005 |
Retter AS, Ando Y, Price DK, Gulley JL, Arlen PM, Steinberg SM, Parker C, Dahut WL, Figg WD. 825: Follow-up Analysis of A Randomized Phase II Study of Docetaxel (D) and Thalidomide (T) in Androgen-Independent Prostate Cancer (AIPC): Updated Survival Data and Stratification by CYP2C19 Mutation Status The Journal of Urology. 173: 224-224. DOI: 10.1016/S0022-5347(18)34994-2 |
0.36 |
|
| 2005 |
Gulley JL, Figg WD, Steinberg SM, Carter J, Hussain M. Erratum: A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase iii clinical trial using limited hormonal therapy (The Journal of Urology (2005) 173 (5) (1567–1571) (S0022534705606246) (10.1097/01.ju.0000154780.72631.85)) The Journal of Urology. 174. DOI: 10.1016/S0022-5347(01)68409-X |
0.323 |
|
| 2004 |
Ng SS, Figg WD. Upregulation of endogenous angiogenesis inhibitors: a mechanism of action of metronomic chemotherapy. Cancer Biology & Therapy. 3: 1212-3. PMID 15662130 DOI: 10.4161/Cbt.3.12.1369 |
0.355 |
|
| 2004 |
Macpherson GR, Singh AS, Bennett CL, Venzon DJ, Liewehr DJ, Franks ME, Dahut WL, Kantoff PW, Price DK, Figg WD. Genotyping and functional analysis of the D104N variant of human endostatin. Cancer Biology & Therapy. 3: 1298-303. PMID 15662127 DOI: 10.4161/Cbt.3.12.1453 |
0.365 |
|
| 2004 |
Tohnya TM, Figg WD. Immunomodulation of multiple myeloma. Cancer Biology & Therapy. 3: 1060-1061. PMID 15640623 DOI: 10.4161/Cbt.3.11.1303 |
0.33 |
|
| 2004 |
Figg WD, Franks ME, Venzon D, Duray P, Cox MC, Linehan WM, Van Bingham W, Eastham JA, Reed E, Sartor O. Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer. World Journal of Urology. 22: 425-30. PMID 15592675 DOI: 10.1007/S00345-004-0443-7 |
0.415 |
|
| 2004 |
Mathijssen Ron HHJ, de Jong FA, van Schaik RHN, Lepper ER, Friberg LE, Rietveld T, de Bruijn P, Graveland WJ, Figg WD, Verweij J, Sparreboom A. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes Journal of the National Cancer Institute. 96: 1585-1592. PMID 15523087 DOI: 10.1093/Jnci/Djh298 |
0.337 |
|
| 2004 |
Tan AR, Yang X, Berman A, Zhai S, Sparreboom A, Parr AL, Chow C, Brahim JS, Steinberg SM, Figg WD, Swain SM. Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer Clinical Cancer Research. 10: 5038-5047. PMID 15297405 DOI: 10.1158/1078-0432.Ccr-04-0025 |
0.362 |
|
| 2004 |
Acharya MR, Venitz J, Figg WD, Sparreboom A. Chemically modified tetracyclines as inhibitors of matrix metalloproteinases. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 7: 195-208. PMID 15296861 DOI: 10.1016/J.Drup.2004.04.002 |
0.303 |
|
| 2004 |
Tan AR, Yang X, Hewitt SM, Berman A, Lepper ER, Sparreboom A, Parr AL, Figg WD, Chow C, Steinberg SM, Bacharach SL, Whatley M, Carrasquillo JA, Brahim JS, Ettenberg SA, et al. Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 3080-90. PMID 15284258 DOI: 10.1200/Jco.2004.08.189 |
0.312 |
|
| 2004 |
Bates SE, Bakke S, Kang M, Robey RW, Zhai S, Thambi P, Chen CC, Patil S, Smith T, Steinberg SM, Merino M, Goldspiel B, Meadows B, Stein WD, Choyke P, ... ... Figg WD, et al. A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 4724-33. PMID 15269145 DOI: 10.1158/1078-0432.Ccr-0829-03 |
0.339 |
|
| 2004 |
Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, Wright JJ, Parnes H, Chen CC, Jones E, Parker CE, Linehan WM, Figg WD. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 2532-9. PMID 15226321 DOI: 10.1200/Jco.2004.05.074 |
0.305 |
|
| 2004 |
Ng SS, MacPherson GR, Gütschow M, Eger K, Figg WD. Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 4192-7. PMID 15217957 DOI: 10.1158/1078-0432.Ccr-03-0700 |
0.413 |
|
| 2004 |
Macpherson GR, Figg WD. Small molecule-mediated anti-cancer therapy via hypoxia-inducible factor-1 blockade. Cancer Biology & Therapy. 3: 503-4. PMID 15197355 DOI: 10.4161/Cbt.3.6.961 |
0.368 |
|
| 2004 |
Lakhani NJ, Sparreboom A, Dahut WL, Venitz J, Figg WD. Determination of the antiangiogenesis agent 2-methoxyestradiol in human plasma by liquid chromatography with ultraviolet detection. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 806: 289-93. PMID 15171941 DOI: 10.1016/J.Jchromb.2004.03.046 |
0.593 |
|
| 2004 |
Paoluzzi L, Figg WD. Histone deacetylase inhibitors are potent radiation protectants. Cancer Biology & Therapy. 3: 612-613. PMID 15136769 DOI: 10.4161/Cbt.3.7.931 |
0.311 |
|
| 2004 |
Tohnya TM, Kim S, Fine HA, Dunn L, Figg WD, Sparreboom A. Determination of SU5416, a novel angiogenesis inhibitor, in human plasma by liquid chromatography. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 805: 135-40. PMID 15113549 DOI: 10.1016/J.Jchromb.2004.02.036 |
0.313 |
|
| 2004 |
Tohnya TM, Ng SS, Dahut WL, Wright JJ, Arlen PM, Gulley JL, Parker C, Zeldis J, Figg WD. A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer. Clinical Prostate Cancer. 2: 241-3. PMID 15072608 DOI: 10.3816/Cgc.2004.N.006 |
0.308 |
|
| 2004 |
Arlen PM, Figg WD, Gulley J, Cox MC, Linehan WM, Dahut W. National Cancer Institute intramural approach to advanced prostate cancer. Clinical Prostate Cancer. 1: 153-62. PMID 15046690 DOI: 10.3816/Cgc.2002.N.017 |
0.414 |
|
| 2004 |
Retter AS, Figg WD, Dahut WL. The combination of antiangiogenic and cytotoxic agents in the treatment of prostate cancer. Clinical Prostate Cancer. 2: 153-9. PMID 15040858 DOI: 10.3816/Cgc.2003.N.023 |
0.438 |
|
| 2004 |
Ng SS, Figg WD, Sparreboom A. Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins. Cancer Research. 64: 821-4. PMID 14871806 DOI: 10.1158/0008-5472.Can-03-3391 |
0.314 |
|
| 2004 |
McDonald DM, Teicher BA, Stetler-Stevenson W, Ng SS, Figg WD, Folkman J, Hanahan D, Auerbach R, O'Reilly M, Herbst R, Cheresh D, Gordon M, Eggermont A, Libutti SK. Report from the society for biological therapy and vascular biology faculty of the NCI workshop on angiogenesis monitoring. Journal of Immunotherapy (Hagerstown, Md. : 1997). 27: 161-75. PMID 14770088 DOI: 10.1097/00002371-200403000-00010 |
0.317 |
|
| 2004 |
Singh AS, Figg W. Upregulation of the androgen receptor during prostate cancer progression. Cancer Biology & Therapy. 3: 284-285. PMID 14764990 DOI: 10.4161/Cbt.3.3.785 |
0.383 |
|
| 2004 |
Sparreboom A, Danesi R, Ando Y, Chan J, Figg WD. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 6: 71-84. PMID 12729805 DOI: 10.1016/S1368-7646(03)00005-0 |
0.326 |
|
| 2004 |
Kumar S, Raje N, Hideshima T, Ishitsuka K, Roccaro A, Shiraishi N, Hamasaki M, Yasui H, Munshi NC, Figg WD, Anderson KC. Anti-Myeloma Activity of Two Novel N-Substituted and Tetraflourinated Thalidomide Analogues. Blood. 104: 2406-2406. DOI: 10.1182/Blood.V104.11.2406.2406 |
0.352 |
|
| 2004 |
Rudek M, Smith N, Zhao M, He P, Lepper E, Figg W, Colevas A, Baker S, Sparreboom A. 520 Modulation of N,N-dimethylamino-benzoylphenylurea (BPU) absorption by the CYP3A and ABCG2 inhibitor ritonavir European Journal of Cancer Supplements. 2: 159. DOI: 10.1016/S1359-6349(04)80528-7 |
0.411 |
|
| 2004 |
Franks ME, Price DK, Macpherson G, Singh A, Linehan WM, Bennett CL, Figg WD. 423: Evaluation of the Endostatin Polymorphism D104N in Prostate Cancer Journal of Urology. 171: 111-112. DOI: 10.1016/S0022-5347(18)37685-7 |
0.376 |
|
| 2004 |
Franks ME, Posadas E, Macpherson G, Dahut W, Linehan WM, Price DK, Figg WD. 395: Leukapheresis of Patients with Androgen Independent Prostate Cancer (AIPC) May Enhance in Vitro Isolation of Prostate Cancer Cells Journal of Urology. 171: 104-104. DOI: 10.1016/S0022-5347(18)37657-2 |
0.399 |
|
| 2004 |
Smith NF, Figg WD, Sparreboom A. Recent advances in pharmacogenetic approaches to anticancer drug development Drug Development Research. 62: 233-253. DOI: 10.1002/Ddr.10361 |
0.346 |
|
| 2003 |
Franks ME, Macpherson GR, Lepper ER, Figg WD, Sparreboom A. New directions in cancer research 2003: technological advances in biology, drug resistance, and molecular pharmacology. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 6: 301-12. PMID 14744494 DOI: 10.1016/J.Drup.2003.09.002 |
0.357 |
|
| 2003 |
Lakhani NJ, Venitz J, Figg WD, Sparreboom A. Pharmacogenetics of estrogen metabolism and transport in relation to cancer. Current Drug Metabolism. 4: 505-13. PMID 14683478 DOI: 10.2174/1389200033489244 |
0.649 |
|
| 2003 |
Hussain MM, Kotz H, Minasian L, Premkumar A, Sarosy G, Reed E, Zhai S, Steinberg SM, Raggio M, Oliver VK, Figg WD, Kohn EC. Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 4356-63. PMID 14645425 DOI: 10.1200/Jco.2003.04.136 |
0.331 |
|
| 2003 |
Rudek MA, Bauer KS, Lush RM, Stinson SF, Senderowicz AM, Headlee DJ, Arbuck SG, Cox MC, Murgo AJ, Sausville EA, Figg WD. Clinical pharmacology of flavopiridol following a 72-hour continuous infusion. The Annals of Pharmacotherapy. 37: 1369-74. PMID 14519054 DOI: 10.1345/Aph.1C404 |
0.57 |
|
| 2003 |
Rudek MA, Venitz J, Ando Y, Reed E, Pluda JM, Figg WD. Factors involved in the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer: clinical and experimental studies. Journal of Clinical Pharmacology. 43: 1124-35. PMID 14517195 DOI: 10.1177/0091270003256675 |
0.572 |
|
| 2003 |
Kurdziel KA, Figg WD, Carrasquillo JA, Huebsch S, Whatley M, Sellers D, Libutti SK, Pluda JM, Dahut W, Reed E, Bacharach SL. Using positron emission tomography 2-deoxy-2-[18F]fluoro-D-glucose, 11CO, and 15O-water for monitoring androgen independent prostate cancer. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 5: 86-93. PMID 14499149 DOI: 10.1016/S1536-1632(03)00039-8 |
0.327 |
|
| 2003 |
Hamilton M, Dahut W, Brawley O, Davis P, Wells-Jones T, Kohler D, Duray P, Liewehr DJ, Lakhani N, Steinberg SM, Figg WD, Reed E. A phase I/II study of high-dose tamoxifen in combination with vinblastine in patients with androgen-independent prostate cancer. Acta Oncologica (Stockholm, Sweden). 42: 195-201. PMID 12852695 DOI: 10.1080/02841860310010718 |
0.678 |
|
| 2003 |
Fine HA, Wen PY, Maher EA, Viscosi E, Batchelor T, Lakhani N, Figg WD, Purow BW, Borkowf CB. Phase II Trial of Thalidomide and Carmustine for Patients With Recurrent High-Grade Gliomas Journal of Clinical Oncology. 21: 2299-2304. PMID 12805330 DOI: 10.1200/Jco.2003.08.045 |
0.649 |
|
| 2003 |
Horne MK, Figg WD, Arlen P, Gulley J, Parker C, Lakhani N, Parnes H, Dahut WL. Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer. Pharmacotherapy. 23: 315-8. PMID 12627929 DOI: 10.1592/Phco.23.3.315.32106 |
0.694 |
|
| 2003 |
Lakhani NJ, Sarkar MA, Venitz J, Figg WD. 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy. 23: 165-72. PMID 12587805 DOI: 10.1592/Phco.23.2.165.32088 |
0.689 |
|
| 2003 |
Zhai S, Sausville EA, Senderowicz AM, Ando Y, Headlee D, Messmann RA, Arbuck S, Murgo AJ, Melillo G, Fuse E, Figg WD. Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms. Anti-Cancer Drugs. 14: 125-35. PMID 12569299 DOI: 10.1097/00001813-200302000-00006 |
0.323 |
|
| 2003 |
UCHIO EM, LINEHAN WM, FIGG WD, WALTHER MM. A Phase I Study of Intravesical Suramin for the Treatment of Superficial Transitional Cell Carcinoma of the Bladder Journal of Urology. 169: 357-360. DOI: 10.1016/S0022-5347(05)64126-2 |
0.334 |
|
| 2002 |
Ando Y, Price DK, Dahut WL, Cox MC, Reed E, Figg WD. Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide. Cancer Biology & Therapy. 1: 669-673. PMID 12642692 DOI: 10.4161/Cbt.318 |
0.386 |
|
| 2002 |
Marshall JL, Rizvi N, Kauh J, Dahut W, Figuera M, Kang MH, Figg WD, Wainer I, Chaissang C, Zhaoyang Li M, Hawkins MJ. A phase I trial of Depsipeptide (FR901228) in patients with advanced cancer Journal of Experimental Therapeutics and Oncology. 2: 325-332. PMID 12440223 DOI: 10.1046/J.1359-4117.2002.01039.X |
0.382 |
|
| 2002 |
Macpherson GR, Ng SS, Lakhani NJ, Price DK, Venitz J, Figg WD. Antiangiogenesis therapeutic strategies in prostate cancer. Cancer Metastasis Reviews. 21: 93-106. PMID 12400998 DOI: 10.1007/0-306-48143-X_20 |
0.696 |
|
| 2002 |
Bennett CL, Price DK, Kim S, Liu D, Jovanovic BD, Nathan D, Johnson ME, Montgomery JS, Cude K, Brockbank JC, Sartor O, Figg WD. Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 3599-604. PMID 12202660 DOI: 10.1200/Jco.2002.11.085 |
0.384 |
|
| 2002 |
Kaur M, Reed E, Sartor O, Dahut W, Figg WD. Suramin's development: what did we learn? Investigational New Drugs. 20: 209-19. PMID 12099581 DOI: 10.1023/A:1015666024386 |
0.442 |
|
| 2002 |
Figg WD, Kruger EA, Price DK, Kim S, Dahut WD. Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer. Investigational New Drugs. 20: 183-94. PMID 12099578 DOI: 10.1023/A:1015626410273 |
0.428 |
|
| 2002 |
Rudek MA, Venitz J, Figg WD. Matrix metalloproteinase inhibitors: do they have a place in anticancer therapy? Pharmacotherapy. 22: 705-20. PMID 12066962 DOI: 10.1592/Phco.22.9.705.34062 |
0.509 |
|
| 2002 |
Bates SE, Chen C, Robey R, Kang M, Figg WD, Fojo T. Reversal of multidrug resistance: Lessons from clinical oncology Novartis Foundation Symposium. 243: 83-102. PMID 11990784 DOI: 10.1002/0470846356.Ch7 |
0.339 |
|
| 2002 |
Neelapu S, Figg WD, Dahut W, Reed E. Leptomeningeal carcinomatosis in metastatic prostate cancer. Southern Medical Journal. 95: 107-8. PMID 11827241 DOI: 10.1097/00007611-200201000-00022 |
0.387 |
|
| 2002 |
Cude KJ, Montgomery JS, Price DK, Dixon SC, Kincaid RL, Kovacs KF, Venzon DJ, Liewehr DJ, Johnson ME, Reed E, Figg WD. The role of an androgen receptor polymorphism in the clinical outcome of patients with metastatic prostate cancer. Urologia Internationalis. 68: 16-23. PMID 11803263 DOI: 10.1159/000048412 |
0.374 |
|
| 2002 |
Cianfrocca M, Cooley TP, Lee JY, Rudek MA, Scadden DT, Ratner L, Pluda JM, Figg WD, Krown SE, Dezube BJ. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 153-9. PMID 11773164 DOI: 10.1200/Jco.20.1.153 |
0.459 |
|
| 2002 |
Kruger EA, Duray PH, Price DK, Pluda JM, Figg WD. Approaches to preclinical screening of antiangiogenic agents. Seminars in Oncology. 28: 570-6. PMID 11740811 DOI: 10.1016/S0093-7754(01)90026-0 |
0.322 |
|
| 2002 |
Tan AR, Headlee D, Messmann R, Sausville EA, Arbuck SG, Murgo AJ, Melillo G, Zhai S, Figg WD, Swain SM, Senderowicz AM. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms Journal of Clinical Oncology. 20: 4074-4082. DOI: 10.1200/Jco.2002.01.043 |
0.307 |
|
| 2001 |
Figg WD, Arlen P, Gulley J, Fernandez P, Noone M, Fedenko K, Hamilton M, Parker C, Kruger EA, Pluda J, Dahut WL. A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Seminars in Oncology. 28: 62-6. PMID 11685731 DOI: 10.1016/S0093-7754(01)90157-5 |
0.351 |
|
| 2001 |
Montgomery JS, Price DK, Figg WD. The androgen receptor gene and its influence on the development and progression of prostate cancer. The Journal of Pathology. 195: 138-46. PMID 11592091 DOI: 10.1002/1096-9896(200109)195:2<138::Aid-Path961>3.0.Co;2-Y |
0.388 |
|
| 2001 |
Chang E, Alexander HR, Libutti SK, Hurst R, Zhai S, Figg WD, Bartlett DL. Laparoscopic continuous hyperthermic peritoneal perfusion. Journal of the American College of Surgeons. 193: 225-229. PMID 11491455 DOI: 10.1016/S1072-7515(01)00980-2 |
0.328 |
|
| 2001 |
Ghate JV, Turner ML, Rudek MA, Figg WD, Dahut W, Dyer V, Pluda JM, Reed E. Drug-induced lupus associated with COL-3: report of 3 cases. Archives of Dermatology. 137: 471-4. PMID 11295928 |
0.512 |
|
| 2001 |
Rudek MA, Horne M, Figg WD, Dahut W, Dyer V, Pluda JM, Reed E. Reversible sideroblastic anemia associated with the tetracycline analogue COL-3. American Journal of Hematology. 67: 51-3. PMID 11279658 DOI: 10.1002/Ajh.1076 |
0.576 |
|
| 2001 |
Blagosklonny MV, Dixon SC, Robey R, Figg WD. Resistance to growth inhibitory and apoptotic effects of phorbol ester and UCN-01 in aggressive cancer cell lines. International Journal of Oncology. 18: 697-704. PMID 11251163 DOI: 10.3892/Ijo.18.4.697 |
0.368 |
|
| 2001 |
Rudek MA, Figg WD, Dyer V, Dahut W, Turner ML, Steinberg SM, Liewehr DJ, Kohler DR, Pluda JM, Reed E. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 19: 584-92. PMID 11208854 DOI: 10.1200/Jco.2001.19.2.584 |
0.572 |
|
| 2001 |
Bartlett DL, Libutti SK, Figg WD, Fraker DL, Alexander HR. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer Surgery. 129: 176-187. PMID 11174711 DOI: 10.1067/Msy.2001.110365 |
0.339 |
|
| 2001 |
Sunwoo JB, Herscher LL, Kroog GS, Thomas GR, Ondrey FG, Duffey DC, Solomon BI, Boss C, Albert PS, McCullugh L, Rudy S, Muir C, Zhai S, Figg WD, Cook JA, et al. Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 19: 800-11. PMID 11157034 DOI: 10.1200/Jco.2001.19.3.800 |
0.327 |
|
| 2001 |
Kruger EA, Figg WD. TNP-470: an angiogenesis inhibitor in clinical development for cancer. Expert Opinion On Investigational Drugs. 9: 1383-96. PMID 11060750 DOI: 10.1517/13543784.9.6.1383 |
0.417 |
|
| 2000 |
Kurdziel K, Bacharach S, Carrasquillo J, Huebsch S, Whatley M, Sellers D, Steinberg S, Libutti S, Pluda J, Reed E, Dahut W, Figg W. 8:45-9:00. Using PET 18F-FDG, 11CO, and 15O-water for Monitoring Prostate Cancer During a Phase II Anti-angiogenic Drug Trial with Thalidomide. Clinical Positron Imaging : Official Journal of the Institute For Clinical P.E.T. 3: 144. PMID 11150747 DOI: 10.1016/S1095-0397(00)00056-X |
0.33 |
|
| 2000 |
Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, Eng C, Spiegelman BM, Kantoff PW. Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer Proceedings of the National Academy of Sciences of the United States of America. 97: 10990-10995. PMID 10984506 DOI: 10.1073/Pnas.180329197 |
0.305 |
|
| 2000 |
Bauer KS, Lush RM, Rudek MA, Shih C, Sausville E, Figg WD. A high-performance liquid chromatography method using ultraviolet and fluorescence detection for the quantitation of UCN-01, 7-hydroxystaurosporine, from human plasma and saliva. Biomedical Chromatography : Bmc. 14: 338-43. PMID 10960835 DOI: 10.1002/1099-0801(200008)14:5<338::Aid-Bmc993>3.0.Co;2-6 |
0.516 |
|
| 2000 |
Rudek MA, March CL, Bauer KS, Pluda JM, Figg WD. High-performance liquid chromatography with mass spectrometry detection for quantitating COL-3, a chemically modified tetracycline, in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 22: 1003-14. PMID 10857569 DOI: 10.1016/S0731-7085(00)00257-0 |
0.517 |
|
| 2000 |
Kang MH, Figg WD, Dahut W. Taxanes in hormone-refractory prostate cancer. Cancer Practice. 7: 270-2. PMID 10687598 DOI: 10.1046/J.1523-5394.1999.75005.X |
0.383 |
|
| 2000 |
Kruger EA, Duray PH, Tsokos MG, Venzon DJ, Libutti SK, Dixon SC, Rudek MA, Pluda J, Allegra C, Figg WD. Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay. Biochemical and Biophysical Research Communications. 268: 183-91. PMID 10652234 DOI: 10.1006/Bbrc.1999.2018 |
0.508 |
|
| 2000 |
Kruger EA, Blagosklonny MV, Dixon SC, Figg WD. UCN-01, a protein kinase C inhibitor, inhibits endothelial cell proliferation and angiogenic hypoxic response. Invasion & Metastasis. 18: 209-18. PMID 10640907 DOI: 10.1159/000024514 |
0.365 |
|
| 2000 |
Senderowicz AM, Reid R, Headlee D, Abornathy T, Horti J, Lush RM, Reed E, Figg WD, Sausville EA. A phase II trial of gallium nitrate in patients with androgen-metastatic prostate cancer. Urologia Internationalis. 63: 120-5. PMID 10592501 DOI: 10.1159/000030430 |
0.422 |
|
| 2000 |
BLAGOSKLONNY MV, DIXON SC, FIGG WD. EFFICACY OF MICROTUBULE-ACTIVE DRUGS FOLLOWED BY KETOCONAZOLE IN HUMAN METASTATIC PROSTATE CANCER CELL LINES Journal of Urology. 163: 1022-1026. DOI: 10.1016/S0022-5347(05)67875-5 |
0.403 |
|
| 1999 |
Saif M, Figg W, Hewitt S, Brosky K, Reed E, Dahut W. Malignant ascites as only manifestation of metastatic prostate cancer. Prostate Cancer and Prostatic Diseases. 2: 290-293. PMID 12497177 DOI: 10.1038/Sj.Pcan.4500385 |
0.382 |
|
| 1999 |
Lush RM, Rudek MA, Figg WD. Review of Three New Agents That Target Angiogenesis, Matrix Metalloproteinases, and Cyclin-Dependent Kinases. Cancer Control : Journal of the Moffitt Cancer Center. 6: 459-465. PMID 10758577 |
0.491 |
|
| 1999 |
Cude KJ, Dixon SC, Guo Y, Lisella J, Figg WD. The androgen receptor: genetic considerations in the development and treatment of prostate cancer. Journal of Molecular Medicine (Berlin, Germany). 77: 419-26. PMID 10426191 DOI: 10.1007/S001090050372 |
0.39 |
|
| 1999 |
Cho HK, Lush RM, Bartlett DL, Alexander HR, Wu PC, Libutti SK, Lee KB, Venzon DJ, Bauer KS, Reed E, Figg WD. Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosis. Journal of Clinical Pharmacology. 39: 394-401. PMID 10197298 DOI: 10.1177/00912709922007967 |
0.326 |
|
| 1999 |
Horti J, Dixon SC, Logothetis CJ, Guo Y, Reed E, Figg WD. Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor. British Journal of Cancer. 79: 1588-93. PMID 10188911 DOI: 10.1038/Sj.Bjc.6690253 |
0.38 |
|
| 1999 |
Melchior SW, Brown LG, Figg WD, Quinn JE, Santucci RA, Brunner J, Thüroff JW, Lange PH, Vessella RL. Effects of phenylbutyrate on proliferation and apoptosis in human prostate cancer cells in vitro and in vivo. International Journal of Oncology. 14: 501-8. PMID 10024683 DOI: 10.3892/ijo.14.3.501 |
0.301 |
|
| 1999 |
Figg WD, Raje S, Bauer KS, Tompkins A, Venzon D, Bergan R, Chen A, Hamilton M, Pluda J, Reed E. Pharmacokinetics of thalidomide in an elderly prostate cancer population Journal of Pharmaceutical Sciences. 88: 121-125. PMID 9874712 DOI: 10.1021/Js980172I |
0.302 |
|
| 1999 |
Reed E, Matthews D, Dyer V, Figg WD. Meningeal Carcinomatosis in Metastatic Prostate Cancer: A Case Report The Prostate Journal. 1: 99-102. DOI: 10.1046/J.1525-1411.1999.09912.X |
0.366 |
|
| 1999 |
RUDEK M, DYER V, HAMILTON J, PLUDA J, REED E, FIGG W. Preliminary pharmacokinetics (PK) of COL-3, a matrix metalloproteinase (MMP) inhibitor Clinical Pharmacology & Therapeutics. 65: 195-195. DOI: 10.1016/S0009-9236(99)80308-7 |
0.482 |
|
| 1998 |
Bauer KS, Kohn EC, Lush RM, Steinberg SM, Davis P, Kohler D, Reed E, Figg WD. Pharmacokinetics and relative bioavailability of carboxyamido-triazole with respect to food and time of administration: Use of a single model for simultaneous determination of changing parameters Journal of Pharmacokinetics and Biopharmaceutics. 26: 673-687. PMID 10485080 DOI: 10.1023/A:1020750923542 |
0.338 |
|
| 1998 |
Sausville EA, Lush RD, Headlee D, Smith AC, Figg WD, Arbuck SG, Senderowicz AM, Fuse E, Tanii H, Kuwabara T, Kobayashi S. Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models. Cancer Chemotherapy and Pharmacology. S54-9. PMID 9750030 DOI: 10.1007/S002800051080 |
0.317 |
|
| 1998 |
Bartlett DL, Buell JF, Libutti SK, Reed E, Lee KB, Figg WD, Venzon DJ, Alexander HR. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis. Cancer. 83: 1251-61. PMID 9740093 DOI: 10.1002/(Sici)1097-0142(19980915)83:6<1251::Aid-Cncr27>3.0.Co;2-3 |
0.333 |
|
| 1998 |
Sartor O, Weinberger M, Moore A, Li A, Figg WD. Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. Urology. 52: 252-6. PMID 9697790 DOI: 10.1016/S0090-4295(98)00149-6 |
0.382 |
|
| 1998 |
Horti J, Figg WD, Weinberger B, Kohler D, Sartor O. A phase II study of bromocriptine in patients with androgen-independent prostate cancer. Oncology Reports. 5: 893-6. PMID 9625840 DOI: 10.3892/Or.5.4.893 |
0.441 |
|
| 1998 |
Thibault A, Figg WD, Bergan RC, Lush RM, Myers CE, Tompkins A, Reed E, Samid D. A Phase II Study of 5-AZA-2'Deoxycytidine (Decitabine) in Hormone Independent Metastatic (D2) Prostate Cancer Tumori Journal. 84: 87-89. DOI: 10.1177/030089169808400120 |
0.447 |
|
| 1997 |
Walsh TJ, Whitcomb P, Piscitelli S, Figg WD, Hill S, Chanock SJ, Jarosinski P, Gupta R, Pizzo PA. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrobial Agents and Chemotherapy. 41: 1944-8. PMID 9303390 DOI: 10.1128/Aac.41.9.1944 |
0.317 |
|
| 1997 |
Dawson NA, Figg WD, Cooper MR, Sartor O, Bergan RC, Senderowicz AM, Steinberg SM, Tompkins A, Weinberger B, Sausville EA, Reed E, Myers CE. Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 15: 1470-7. PMID 9193342 DOI: 10.1200/Jco.1997.15.4.1470 |
0.415 |
|
| 1997 |
Kohn EC, Figg WD, Sarosy GA, Bauer KS, Davis PA, Soltis MJ, Thompkins A, Liotta LA, Reed E. Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: Pharmacokinetics, clinical outcome, and comparison of formulations Journal of Clinical Oncology. 15: 1985-1993. PMID 9164210 DOI: 10.1200/Jco.1997.15.5.1985 |
0.372 |
|
| 1997 |
Piscitelli SC, Reiss WG, Figg WD, Petros WP. Pharmacokinetic studies with recombinant cytokines. Scientific issues and practical considerations. Clinical Pharmacokinetics. 32: 368-81. PMID 9160171 DOI: 10.2165/00003088-199732050-00003 |
0.304 |
|
| 1997 |
Figg WD, Christian MC, Lush R, Link CJ, Davis P, Kohn E, Sarosy G, Rothenberg ML, Weiss RB, Ryan N, Jacobs J, Reed E. Pharmacokinetics of elemental platinum (ultrafiltrate and total) after a thirty minute intravenous infusion of ormaplatin. Biopharmaceutics & Drug Disposition. 18: 347-59. PMID 9158882 DOI: 10.1002/(Sici)1099-081X(199705)18:4<347::Aid-Bdd23>3.0.Co;2-O |
0.308 |
|
| 1997 |
Figg WD, Kroog G, Duray P, Walther MM, Patronas N, Sartor O, Reed E. Flutamide withdrawal plus hydrocortisone resulted in clinical complete response in a patient with prostate carcinoma. Cancer. 79: 1964-8. PMID 9149024 DOI: 10.1002/(Sici)1097-0142(19970515)79:10<1964::Aid-Cncr18>3.0.Co;2-T |
0.37 |
|
| 1997 |
Dixon SC, Zalles A, Giordano C, Lush RM, Venzon D, Reed E, Figg WD. In vitro effect of gallium nitrate when combined with ketoconazole in the prostate cancer cell line PC-3. Cancer Letters. 113: 111-6. PMID 9065809 DOI: 10.1016/S0304-3835(97)04603-X |
0.424 |
|
| 1997 |
Lush RM, Meadows B, Fojo AT, Kalafsky G, Smith HT, Bates S, Figg WD. Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist. Journal of Clinical Pharmacology. 37: 123-8. PMID 9055138 DOI: 10.1002/J.1552-4604.1997.Tb04770.X |
0.35 |
|
| 1997 |
Lush RM, Figg WD, Pluda JM, Bitton R, Headlee D, Kohler D, Reed E, Sartor O, Cooper MR. A phase I study of pentosan polysulfate sodium in patients with advanced malignancies. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 7: 939-44. PMID 9006745 DOI: 10.1093/Oxfordjournals.Annonc.A010797 |
0.342 |
|
| 1997 |
Dixon SC, Soriano BJ, Lush RM, Borner MM, Figg WD. Apoptosis: its role in the development of malignancies and its potential as a novel therapeutic target. The Annals of Pharmacotherapy. 31: 76-82. PMID 8997471 DOI: 10.1177/106002809703100113 |
0.304 |
|
| 1997 |
Boudoulas S, Lush RM, McCall NA, Samid D, Reed E, Figg WD. Plasma protein binding of phenylacetate and phenylbutyrate, two novel antineoplastic agents. Therapeutic Drug Monitoring. 18: 714-20. PMID 8946671 DOI: 10.1097/00007691-199612000-00015 |
0.317 |
|
| 1997 |
Simmons BR, Bauer KS, McCall NA, Kohn EC, Figg WD. An Optimized Method for the quantitation of Carboxyamidotriazole (CAI) in Human Plasma with Solid Phase Extraction and reversed Phase HPLC Analytical Letters. 30: 2009-2021. DOI: 10.1080/00032719708001717 |
0.301 |
|
| 1997 |
Simmons BR, Lush RM, Figg WD. A reversed-phase high performance liquid chromatography method using solid phase extraction to quantitate thalidomide in human serum Analytica Chimica Acta. 339: 91-97. DOI: 10.1016/S0003-2670(96)00494-1 |
0.32 |
|
| 1997 |
Figg WD, Pluda JM, Lush RM, Saville MW, Wyvill K, Reed E, Yarchoan R. The Pharmacokinetics of TNP‐470, a New Angiogenesis Inhibitor Pharmacotherapy. 17: 91-97. DOI: 10.1002/J.1875-9114.1997.Tb03680.X |
0.365 |
|
| 1997 |
Piscitelli SC, Forrest A, Lush RM, Ryan N, Whitfield LR, Figg WD. Pharmacometric Analysis of the Effect of Furosemide on Suramin Pharmacokinetics Pharmacotherapy. 17: 431-437. DOI: 10.1002/J.1875-9114.1997.Tb03053.X |
0.359 |
|
| 1996 |
Figg WD, Ammerman K, Patronas N, Steinberg SM, Walls RG, Dawson N, Reed E, Sartor O. Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer Cancer Investigation. 14: 513-517. PMID 8951355 DOI: 10.3109/07357909609076896 |
0.379 |
|
| 1996 |
Figg WD, Dawson N, Middleman MN, Brawley O, Lush RM, Senderowicz A, Steinberg SH, Tompkins A, Reed E, Sartor O. Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with hormone refractory prostate cancer. Acta Oncologica (Stockholm, Sweden). 35: 763-5. PMID 8938230 DOI: 10.3109/02841869609084015 |
0.385 |
|
| 1996 |
Walls R, Thibault A, Liu L, Wood C, Kozlowski JM, Figg WD, Sampson ML, Elin RJ, Samid D. The differentiating agent phenylacetate increases prostate-specific antigen production by prostate cancer cells. The Prostate. 29: 177-82. PMID 8827086 DOI: 10.1002/(Sici)1097-0045(199609)29:3<177::Aid-Pros3>3.0.Co;2-B |
0.424 |
|
| 1996 |
Walther MM, Figg WD, Linehan WM. Intravesical suramin: a novel agent for the treatment of superficial transitional-cell carcinoma of the bladder World Journal of Urology. 14. PMID 8738403 DOI: 10.1007/Bf00182057 |
0.346 |
|
| 1996 |
Sartor O, Figg WD. Mifepristone: antineoplastic studies. Clinical Obstetrics and Gynecology. 39: 498-505. PMID 8734014 DOI: 10.1097/00003081-199606000-00023 |
0.353 |
|
| 1996 |
Middleman MN, Lush RM, Sartor O, Reed E, Figg WD. Treatment approaches for metastatic cancer of the prostate based on recent molecular evidence. Cancer Treatment Reviews. 22: 105-18. PMID 8665563 DOI: 10.1016/S0305-7372(96)90030-4 |
0.376 |
|
| 1996 |
Dawson NA, Cooper MR, Figg WD, Headlee DJ, Thibault A, Bergan RC, Steinberg SM, Sausville EA, Myers CE, Sartor O. Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer. 76: 453-62. PMID 8625127 DOI: 10.1002/1097-0142(19950801)76:3<453::Aid-Cncr2820760316>3.0.Co;2-E |
0.429 |
|
| 1996 |
Tisdale JF, Figg WD, Reed E, McCall NA, Alkins BR, Horne MK. Severe thrombocytopenia in patients treated with suramin: evidence for an immune mechanism in one. American Journal of Hematology. 51: 152-157. PMID 8579057 DOI: 10.1002/(Sici)1096-8652(199602)51:2<152::Aid-Ajh10>3.0.Co;2-K |
0.365 |
|
| 1996 |
Middleman MN, Lush RM, Figg WD. The Mutated Androgen Receptor and Its Implications for the Treatment of Metastatic Carcinoma of the Prostate Pharmacotherapy. 16: 376-381. DOI: 10.1002/J.1875-9114.1996.Tb02967.X |
0.39 |
|
| 1995 |
Thibault A, Samid D, Cooper MR, Figg WD, Tompkins AC, Patronas N, Headlee DJ, Kohler DR, Venzon DJ, Myers CE. Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer. 75: 2932-8. PMID 7773944 DOI: 10.1002/1097-0142(19950615)75:12<2932::Aid-Cncr2820751221>3.0.Co;2-P |
0.371 |
|
| 1995 |
Piscitelli SC, Thibault A, Figg WD, Tompkins A, Headlee D, Lieberman R, Samid D, Myers CE. Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine. Journal of Clinical Pharmacology. 35: 368-73. PMID 7650225 DOI: 10.1002/J.1552-4604.1995.Tb04075.X |
0.344 |
|
| 1995 |
Bitton RJ, Figg WD, Reed E. A preliminary risk-benefit assessment of paclitaxel. Drug Safety. 12: 196-208. PMID 7619331 DOI: 10.2165/00002018-199512030-00005 |
0.418 |
|
| 1995 |
Figg WD, Sartor O, Cooper MR, Thibault A, Bergan RC, Dawson N, Reed E, Myers CE. Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. The American Journal of Medicine. 98: 412-4. PMID 7535978 DOI: 10.1016/S0002-9343(99)80323-4 |
0.371 |
|
| 1995 |
Figg WD, Thibault A, Cooper MR, Reid R, Headlee D, Dawson N, Kohler DR, Reed E, Sartor O. A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer. Cancer. 75: 2159-64. PMID 7535186 DOI: 10.1002/1097-0142(19950415)75:8<2159::Aid-Cncr2820750820>3.0.Co;2-O |
0.432 |
|
| 1995 |
Sausville E, Headlee D, Stetler-Stevenson M, Jaffe E, Solomon D, Figg W, Herdt J, Kopp W, Rager H, Steinberg S. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study Blood. 85: 3457-3465. DOI: 10.1182/Blood.V85.12.3457.Bloodjournal85123457 |
0.338 |
|
| 1995 |
Middleman MN, Lush RM, Sartor O, Reed E, Figg WD. Prolonged response to flutamide withdrawal and initiation of aminoglutethimide in a patient with metastatic prostate cancer Journal of Oncology Pharmacy Practice. 1: 45-47. DOI: 10.1177/107815529500100309 |
0.406 |
|
| 1994 |
Figg WD, Thibault A, Sartor AO, Mays D, Headlee D, Calis KA, Cooper MR. Hypothyroidism Associated With Aminoglutethimide in Patients With Prostate Cancer Archives of Internal Medicine. 154: 1023-1025. PMID 8179445 DOI: 10.1001/Archinte.1994.00420090113012 |
0.428 |
|
| 1994 |
Figg WD, Cooper MR, Thibault A, Headlee D, Humphrey J, Bergan RC, Reed E, Sartor O. Acute renal toxicity associated with suramin in the treatment of prostate cancer. Cancer. 74: 1612-4. PMID 8062193 DOI: 10.1002/1097-0142(19940901)74:5<1612::Aid-Cncr2820740519>3.0.Co;2-Q |
0.369 |
|
| 1994 |
Figg WD, Walls RG, Cooper MR, Thibault A, Sartor O, McCall NA, Myers CE, Samid D. In vitro antitumor effect of hydroxyurea on hormone-refractory prostate cancer cells and its potentiation by phenylbutyrate Anti-Cancer Drugs. 5: 336-342. PMID 7919459 DOI: 10.1097/00001813-199406000-00012 |
0.433 |
|
| 1993 |
Thibault A, Figg WD, Cooper MR, Prindiville SA, Sartor AO, Headlee DJ, Myers CE. Anaphylactoid Reaction With Suramin Pharmacotherapy. 13: 656-657. DOI: 10.1002/J.1875-9114.1993.Tb02774.X |
0.337 |
|
| Show low-probability matches. |